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CHAPTER 1 
INTRODUCTION 
1. Breast cancer 
Breast cancer is the leading type of cancer and the second most common cause 
of cancer death in American women [1]. The overall lifetime probability of developing 
breast cancer is 1 in 6, and about 1 in 8 women will develop invasive breast cancer in 
the United States [2]. According to 2010 estimates, approximately 207,090 new cases 
of invasive breast cancer would be diagnosed in women in the United States and about 
39,840 women would die from the disease in 2010 [2].  
Treatment options for women with breast cancer include surgery, radiation 
therapy, chemotherapy, hormone therapy, and targeted therapy. The treatment 
decision is made based on the size and location of the tumor in the breast, the results 
of lab tests done on the cancer cells, the stage or extent of the disease, and the age 
and general condition of the patient [3-7].   
Surgery, consisting of lumpectomy (breast-conserving surgery) or mastectomy 
(removal of the whole breast), is usually the first line of treatment for breast cancer, 
especially early-stage primary breast cancer [7]. However, breast cancer can come 
back as a local recurrence (occur in the surgery area), regional recurrence (cancer has 
spread beyond the breast), or as a distant recurrence (also known as metastasis) 
somewhere else such as lymph nodes, the bones, liver, or lungs within the first two 
years if no further treatment is given after surgery [8;9]. Therefore, radiotherapy or 
chemotherapy has become an integral part of post-surgical breast cancer management 
[3;7]. It has been reported that between 5% and 33% of breast cancer patients develop 
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chronic lymphedema after surgery and radiotherapy or chemotherapy, accompanied by 
cognitive changes, early menopause, weight gain, hair loss and changes in skin tone 
and texture, which all result in significant psychosocial morbidity and decreased quality 
of life [10;11]. Thus, patients who prefer to have the best possible quality of life while 
they are being treated tend to choose less-aggressive treatments such as hormone 
therapy and targeted therapy.  
Hormonal therapies, including selective estrogen receptor modulators (SERMs), 
aromatase inhibitors and estrogen receptor down-regulators (ERDs), are used 
to prevent early-stage, hormone receptor-positive breast cancer recurrence after 
surgery and to treat advanced-stage/metastatic hormone-receptor-positive breast 
cancer in both pre- and post-menopausal patients [12]. Targeted cancer therapies 
recognize and block specific characteristics of cancer cells and simultaneously activate 
defense responses. Therefore, targeted therapies are generally less likely than 
chemotherapy to harm normal, healthy cells. Moreover, novel conjugates of antibodies 
with cytotoxic agents that are activated after entering the cancer cell are under 
investigation [13].  
Although these two kinds of less-aggressive treatment are widely used, hormone 
therapies primarily target estrogen receptor (ER)-positive breast cancer, and the 
majority of targeted therapies work specifically against HER2-positive breast cancer 
[12;13]. Neither of these approaches is effective against triple-negative breast cancers 
(TNBC) (ER-, progesterone receptor (PR)-, and HER2-negative). TNBC has become a 
focus of intense research because TNBC patients present at a younger age at onset 
and have a higher tumor grade, larger tumor size, and increased propensity to develop 
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metastases. Most importantly, they lack the three most significant therapeutic markers 
for clinical management resulting in the worst outcome when compared with other 
cancer subtypes, which motivates the investigation of novel approaches for the 
prevention and treatment of this aggressive form of breast cancer [14-18]. Another 
major clinical problem is that the majority of tumors will eventually manifest resistance 
during the course of hormone and targeted therapies [19-21]. Therefore, it is critical to 
identify new therapeutic targets both to improve the prognosis and survival rate of 
patients with all forms of breast cancer and to prevent breast cancer from developing by 
identifying women at increased risk and intervening to modify risk.    
2. Estrogen and breast cancer 
Based on the results of clinical and epidemiological studies, the well-established 
risk factors for breast cancer have been summarized as earlier age at menarche, 
nulliparity, later age at first full-term birth, later age at menopause, history of breast 
cancer in a first-degree relative, and socioeconomic status [22-26]. The majority of 
these risk factors indicate that prolonged cumulative exposure to endogenous estrogen 
may increase the risk of developing breast cancer [27;28]. The estrogen-sensitive 
nature of breast cancer has also been implicated by the fact that surgical removal of 
ovaries significantly reduces breast cancer risk in pre-menopausal women [29;30]. 
About 95% of breast cancer is initially hormone-dependent, which also indicates the 
crucial role of estrogen in breast cancer development and progression [31;32]. 
2.1 Critical estrogen exposure periods 
Emerging evidence supports the hypothesis that there are critical periods during 
a woman's lifetime during which estrogen exposure increases breast cancer. The 
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intrauterine period, adolescence and full-term pregnancy are intervals in which 
mammary tissue undergoes a high rate of proliferation and extensive differentiation. 
Therefore, a high level and/or prolonged duration of estrogen exposure during these 
vulnerable periods may dramatically increase the risk of breast cancer.  
Data from animal and human population studies provide leads to the critical role 
of estrogen exposure in uterus on one‟s risk for breast cancer development later in life. 
During pregnancy, the levels of intrauterine estrogen are at least 10 times higher than 
they are in women who are not pregnant, and the levels gradually increase throughout 
pregnancy [33-35]. The hypothesis that factors positively associated with intrauterine 
estrogen exposure such as gestational age, birth weight and birth length, are positively 
associated with breast cancer risk has been extensively investigated. Examples of 
findings from these studies are the following:  
 Longer gestation is an indicator of prolonged exposure to pregnancy hormones 
and has been postulated to be associated with increased breast cancer risk. 
However, epidemiology studies have not provided consistent supportive results. 
Two matched case-control studies done in either women aged 14-37 years or 
who were twin births support a role for early estrogen exposure in the 
development of breast cancer [36;37]. However, three other cohort studies 
indicate an inverse relationship between gestational age and breast cancer risk 
[38-40].  
 Increased birth weight and length have been demonstrated to be positively 
associated with prolonged in utero estrogen and other maternal hormone 
exposure [41-44]. Studies to date have generally suggested a positive correlation 
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between birth weight and length and breast cancer risk, especially in pre-
menopausal breast cancer cases [36;38;45-48]. A nested case-control study 
within the cohorts of two Nurses‟ Health Studies indicates that pre-menopausal 
breast cancer risk is significantly associated with increased birth weight [46]. This 
finding is consistent with that reported in another British cohort study of 2167 
women (including 59 breast cancer cases, 21 of which were diagnosed before 
menopause), in which women who had high birth weight were five times (relative 
risk=5.03; 95% confidence interval=1.13, 22.5) more likely to develop 
premenopausal breast cancer than were women who had low birth weight (P-
value for linear trend=0.03) [48]. A record linkage study of 373 Norwegian breast 
cancer cases and 1150 age-matched control women provided strong evidence 
that breast cancer risk was positively associated with both birth weight and birth 
length (P for trend=0.02) [47]. The same author conducted another prospective 
population-based study in a cohort of 16,016 women in Norway (including 312 
breast cancer cases) and reported a similar positive association between birth 
weight and length and breast cancer risk [45].    
Animal studies also provide evidence that intrauterine factors influence future 
breast cancer risk [49]. Increased levels of estrogen due to high dietary fat intake in 
pregnant rats enhanced mammary tumor development in first-generation female 
offspring [49;50]. Similarly, a later study provided evidence that the plasma estrogen 
levels of pregnant rats were significantly elevated by feeding them a diet high in n-6 
polyunsaturated fats. This finding indicated that the female offspring of high-fat-fed rats 
were more vulnerable to carcinogen treatment, as manifested by significantly higher 
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mammary tumor incidence and shorter latency, than were the offspring of pregnant rats 
fed a low-fat diet [50].  
In addition to those studies demonstrating that increased exposure to estrogen in 
utero can result in increased breast cancer development during adulthood, two studies 
have demonstrated that offspring of women with preeclampsia, a pregnancy-induced 
condition characterized by decreased levels of pregnancy hormones [51;52], have a 
significantly lower breast cancer risk [40;53].      
In summary, all of the findings described above suggest that prolonged exposure 
to estrogen and other hormonal factors particularly in utero may initiate the carcinogenic 
process in mammary gland tissue and affect breast cancer risk later in life.     
The most dramatic development of breast tissue occurs during puberty when the 
ovaries begin to secrete estrogen and other hormones [54;55]. Therefore, breast 
tissue is most vulnerable to carcinogen exposure during this period. Breast cancer risk 
is closely related to the duration of estrogen exposure that is estimated by the ages of 
menarche and menopause. It has been estimated that breast cancer risk is reduced by 
4 to 20% each year that menarche is delayed [56;57]. Similarly, epidemiology studies 
indicate a 1.5-fold increase in breast cancer risk for women who have an early age of 
menarche [58]. Another factor that can be translated into high estrogen exposure is 
body mass index (BMI). However, BMI is not always positively associated with breast 
cancer, and its association with breast cancer varies by menopause status. Numerous 
case-control studies and cohort studies suggest that BMI is nonlinearly inversely 
associated with breast cancer risk in pre-menopausal women, but nonlinearly positively 
associated with post-menopausal breast cancer risk [59-65]. Some of these studies 
7 
 
 
 
indicate that one‟s BMI at puberty is closely associated with breast cancer risk in adult 
life [61-65]. In a cohort study of 117,415 women (including 3340 cases of breast 
cancer), BMI at 14 years of age was inversely associated with increased breast cancer 
development during adulthood [65]. Four other studies also support this finding [61-64].  
It has been suggested that pregnancy and lactation, especially the first full-term 
pregnancy, completes the full differentiation of breast tissue [66]. Therefore, the breast 
is highly susceptible to the influence of carcinogen during this period. Early age of first 
and second full-term pregnancy and the number of births have been associated with a 
long-term reduction in breast cancer risk, especially for postmenopausal women, 
according to a large scale study including 1.7 million Norwegian women born in the 
period 1925 to 1979 (including 22,890 breast cancer cases at ages 20–74 years) [67]. 
Two epidemiological studies showed that prolonged breastfeeding was associated with 
an additional protective effect against breast cancer development in premenopausal 
women [68;69]. In addition to the repeatedly demonstrated protective effect of early 
first pregnancy and breast-feeding in epidemiological studies, experiments in rodent 
breast cancer models have also confirmed the inverse association between age at first 
pregnancy and breast cancer risk [70-73]. The protective role of reproduction in the 
susceptibility to carcinogen-induced breast cancer is demonstrated by the finding that 
nulliparous rats are highly susceptible to the induction of mammary carcinomas by 
carcinogen 7,12-dimethyl benzanthracene [70-72]. Similarly, the study of Yang et al 
[73] also supports the protective role of parity and lactation against N-methyl-N-
nitrosourea treatment induced mammary carcinogenesis.   
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Therefore, understanding the biology of estrogen in greater depth will facilitate 
the development of new interventions for breast cancer prevention and treatment.    
2.2  Estrogen biosynthesis 
The naturally occurring estrogens, 17β-estradiol (E2), estrone (E1), and estriol 
(E3), are C18 steroids derived from cholesterol, among which E2 is the predominant 
endogenous activator of ER-mediated cellular processes [19]. In premenopausal 
women, the primary source of estrogen is E2 produced by the ovaries with 
concentrations that fluctuate during menstrual cycles from 40 to 250 pg/ml [74]. 
However, in postmenopausal women, the serum E2 concentration is often lower than 
20 pg/ml and E1 becomes the predominant form of estrogen [74]. Adipose tissue is 
another important source of estrogen, particularly in pre-pubertal girls and 
postmenopausal women [75]. 
Although circulating estrogen levels are decreased by 90% in postmenopausal 
women,  the majority of breast carcinomas arise after menopause and the intra 
tumoral concentration of E2 is more than 10 times higher than in plasma [74;76-79]. 
Previous investigations also demonstrated that a large proportion (around 75% in 
premenopausal women and almost 100% in postmenopausal women) of the bio-
available estrogen is derived from de novo biosynthesis in peripheral tissues. Overall, 
this finding highlights the importance of in situ metabolism of estrogen in cancer target 
tissues [80-83]. In the breast, three main pathways are involved in the in situ formation 
of estrogen [84-86]: 
 Aromatase (CYP19) pathway: CYP19 catalyzes the rate-limiting step in the 
conversion of androstenedione taken up by the tumor from the blood into E1, which 
9 
 
 
 
is then converted into E2 by 17-β hydroxysteroid dehydrogenase type 1 (17-β 
HSD1) [87-89]. It has been demonstrated that in situ metabolism of estrogen 
through the CYP19 pathway is correlated with the risk of developing breast cancer 
[22;90]. CYP19 expression is significantly increased in breast carcinoma compared 
to nonmalignant breast tissue, and its expression also increases during breast 
cancer malignant progression, with the highest level in invasive breast carcinoma, 
which supports the therapeutic potential of targeting the CYP19 enzyme for breast 
cancer treatment [91].  
 17β-HSD pathway: The enzymes of the 17β-HSD gene family are responsible for 
the interconversion of dehydroepiandrosterone (DHEA) and testosterone and of E1 
and E2, which indicates that this enzymatic activity is required for the synthesis of all 
androgens and estrogens [18]. The distribution and activity of estrogenic 17β-HSD 
has been studied in 15 human tissues. Estrogenic 17β-HSD activity was detected in 
all tissues examined with the highest rates in placenta, liver, ovary, endometrium, 
testis and adipose tissue [92]. The mRNA levels of 17β-HSD1, which catalyzes the 
reduction of E1 to E2, was significantly higher in breast cancer lesions from 
postmenopausal patients than that in tumor from premenopausal patients, and the 
protein expression of this enzyme was detected in about 60% of breast carcinomas, 
which correlated with ER and PR levels [78;93]. 17β-HSD activity was significantly 
higher in tumoral tissues than in the normal surrounding mammary tissue [78;94;95]. 
 Sulfatase pathway: Steroid sulfatase (STS) converts estrone sulfate taken up by 
the tumor from the blood into E1, and then 17β-HSD1 converts E1 into E2. STS 
expression was detected in approximately 70% of breast carcinoma cases and was 
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higher in breast carcinoma lesions than in the surrounding normal tissue [96-99]. 
STS expression correlates with an increased risk of breast cancer recurrence, poor 
clinical outcome, and a significantly shorter relapse-free survival in breast cancer 
patients, which emphasizes the importance of sulfatase-mediated local production 
of estrogen in the malignant progression of breast carcinomas [96-99].   
2.3  Estrogen carcinogenesis in breast cancer 
Carcinogenesis is a multistage process that includes initiation and promotion 
[100-102]. The initiation of carcinogenesis is an irreversible, direct increase in 
chromosomal aberrations and mutation of oncogenes and tumor suppressor genes 
[100-102]. Promotion is an interruptible or reversible stage during which the initiated 
cells undergo clonal expansion [100-102]. It has been suggested that estrogens are 
unique carcinogens affecting both tumor initiation and promotion. There are mainly two 
mechanistic explanations for the involvement of estrogen in breast cancer processes. 
The classical, well accepted mechanism for the role of estrogen in breast 
carcinogenesis is that estrogens stimulates cell growth, increases the rate of cell 
division and suppresses apoptosis, which can enhance opportunities for DNA mutation 
and render a spontaneous or chemically-induced mutation permanent [103-107]. These 
actions of estrogen can be achieved through pathways mediated by ER. 
There are two ER subtypes, ERα and ERβ, which have different estrogen 
affinities, expression patterns and responses to ER modulators and anti-estrogens 
[108-110]. For instance, E1 and E2 have a higher affinity for ERα, while some 
phytoestrogens bind with higher affinity to ERβ [110]. Endothelial cells, bone and kidney 
express mainly ERβ, while breast cancer cells and ovarian stroma contain mostly ERα 
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[109]. Moreover, ERα and ERβ mediate different transcriptional effects due to the 
distinctive conformations of their major transactivation domains [111;112]. For example, 
E2 might activate transcription when it binds to ERα but display the opposite effect 
when it binds to ERβ [113]. Therefore, the effects of estrogens may vary in different 
tissues and cells, and may even be different in the same cell at different time points due 
to the structure of the hormone, the subtype of ER involved, the characteristics of the 
target gene promoter, and the availability of coactivators and corepressors. 
ERs are mainly functional as ligand-dependent transcription factors [19]. 
Estrogens readily diffuse across the cell membrane and interact with ERs in the nucleus 
where the homodimeric complexes bind to estrogen response elements (EREs) and 
recruit coactivators or corepressors to regulate the transcription of estrogen-responsive 
genes involved in cell proliferation and cell survival [19]. However, recently it has been 
reported that one-third of estrogen regulated-genes do not contain conserved EREs in 
their promoter regions [114]. This finding led to the investigation of ERE-independent 
transcriptional activation by estrogen-ER complexes. In this circumstance, ER binds to 
alternative regulatory DNA sequences such as AP-1, SP-1, cyclic AMP (cAMP)-
response element, and upstream stimulatory factor sites, or acts as a coactivator by 
interacting with other DNA-bound transcription factors, such as c-jun or c-fos proteins, 
to stabilize the DNA binding of the transcription factor complex or recruit other 
coactivators to the complex [115-117]. The expression of a variety of proteins involved 
in cell proliferation and metastasis, such as insulin-like growth factor receptor 1, cyclin 
D1, c-myc, collagenase, and the anti-apoptosis factor Bcl-2, are regulated in this 
manner [116;118-120]. Interruption of ERE-independent transcriptional activation, 
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especially at the AP-1 site, results in the in vivo and in vitro resistance of breast cancer 
cells to growth stimulation by estrogen or other growth factors, which indicates that 
these alternative ER signaling pathways may play an important role in estrogen-
mediated breast cancer development and progression [121].    
In addition to the above mentioned estrogen-dependent transcriptional 
activation, several kinases in the growth factor signaling networks, including mitogen-
activated kinases (MAPK), Akt, p90 ribosomal S6 kinase (p90RSK), protein kinase A 
and c-Src, can also activate ER signaling through an estrogen-independent mechanism 
[122;123]. These kinases can directly phosphorylate several sites of ER such as 
S104/106, S118, S167, T331 and Y153 [124-130]. For example, both the PI3k-Akt and 
MAPK pathways can enhance transcriptional activation of ER by phosphorylating ER at 
serine 167 [124-126]. Additionally, the MAPK pathway can also activate cell 
proliferation and transform cells by phosphorylating ER at serine 118 [127-130]. 
Furthermore, these kinases can also indirectly stimulate ERα transcriptional activity by 
phosphorylating either coactivators for ERα, such as the p160 family coactivator AIB1, 
or other kinases, such as P90RSK, which can then phosphorylate ER [124;131;132].   
These genomic signaling pathways take hours to days to alter responsive genes 
and produce effects on cells. However, there are some rapid responses to estrogen 
simulation that occur in minutes, which can not be accounted for by changes in gene 
expression mediated by nuclear ERs. These rapid responses include the generation of 
second messengers, such as cAMP, Ca
2+
, and nitric oxide, as well as the activation of 
various receptor tyrosine kinase and protein lipid kinase pathways, such as the MAPK 
signaling pathway, which will affect cell adhesion, migration, survival and proliferation 
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[133-139]. These non-genomic effects of estrogen are mediated through a membrane-
bound form of ERα, ERβ, or both, and its cross-talk with other signal transduction 
pathways, such as epidermal growth factor (EGF) receptor and insulin-like growth factor 
receptor-signaling pathways [133;134;140-144]. Alternatively, estrogens might act 
through non-ER-mediated pathways [145].  
In addition to ERs, recent studies indicate that rapid effects of estrogen are also 
mediated by a novel transmembrane G protein-coupled receptor 30 (GPR30), also 
known as G protein-coupled ER, based on correlations of receptor expression with 
estrogen-mediated Erk-1/2 activation, association of receptor with local ER expression 
in breast cancer cell lines, and cellular estrogen binding [146-148]. GPR30 is also 
reported to mediate a c-fos–related, ERE-independent genomic signaling pathway of 
estrogen [149]. In support of the role of GPR30 in mediating estrogen signal 
transduction, several studies report that estrogen can bind to GPR30 with high affinity 
[148;150]. The activated GPR30 can then initiate intracellular second messenger 
signaling pathways and activate Src, which is involved in matrix metalloproteinase 
activation and heparin-binding EGF-like factor (HB-EGF) release [151;152]. Free HB-
EGF can bind EGF receptor and activate multiple downstream events, such as (1) 
activation of phospholipase C that can produce inositol trisphosphate (IP3) to mobilize 
calcium; (2) activation of phosphoinositide 3-kinases and its downstream AKT pathway; 
and (3) activation of MAPK that can lead to the activation of numerous cytosolic 
pathways and nuclear proteins [151-154]. These findings indicate that GPR30 is 
involved in the regulation of cell proliferation, invasion, metastasis and target gene 
expression. Furthermore, decreased expression of GPR30 in human breast cancer and 
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the strong inverse association of GPR30 with cancer cell proliferation, migration, 
invasion, metastasis, differentiation and progression have been reported [149;155-166]. 
In addition, approximately half of classic ER negative breast tumors retain GPR30 
expression, which indicates that these tumors (GPR30+/ER-) may remain responsive to 
estrogen-targeted treatment through the GPR30 signaling pathway [164]. Therefore, 
these important roles of GPR30 in estrogen-induced signal transduction and the strong 
association between GPR30 and breast cancer development and progression indicate 
that GPR30 may be a novel therapeutic target for breast cancer treatment, especially 
for ER negative breast cancer patients.      
Another theory that can explain the involvement of estrogens in breast 
carcinogenesis is that reactive metabolites of estrogens, especially estrogen catechols 
and estrogen quinones, can directly induce mutations [167-175]. Enzymes that are 
involved in estrogen carcinogenic metabolism will be discussed in detail in the following 
sections.  
2.4  Estrogen genotoxic metabolite metabolism 
Once formed, estrogens are subjected to extensive local metabolism, such as 
oxidative and conjugation reactions, that can lead to either their deactivation and 
subsequent elimination or to the generation of genotoxic metabolites [176-178]. 
Therefore, further estrogen metabolism after biosynthesis is of great importance for 
both determining the estrogen levels in breast tissue and breast carcinogenesis. The 
main types of metabolic reactions include oxidation by cytochromes P450 (CYPs), O-
methylation by catechol O-methyltransferase (COMT), glucuronidation by UDP-
glucuronosyl transferases (UGTs), and sulfonation by sulfotransferases (SULTs).    
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Oxidation: Endogenous estrogens undergo oxidative metabolism catalyzed by 
various CYP enzymes in both liver and estrogen target organs (e.g., breast). (Fig. 1.1). 
However, since liver and estrogen target organs express different CYP enzymes, it is 
necessary to consider the specific CYPs that are expressed in human mammary tissue 
when considering the role of CYP-mediated metabolism in local estrogen regulation 
[176;179-182].  
CYP1B1 is over-expressed in many kinds of tumors relative to normal tissues 
[183-186]. CYP1A1 is an inducible enzyme that has high catalytic activity for 2-
hydroxylation (2-OH) of E2 and E1, while CYP1B1 has a distinct, selective activity for 
the 4-hydroxylation (4-OH) of E2 and E1 [187]. Because the expression level of 
CYP1B1 is higher than CYP1A1, 4-hydroxylation is the dominant pathway of E2 
oxidation in human breast and uterus [188;189].  
CYP enzymes also catalyze the further oxidation of the 2-OH and 4-OH catechol 
estrogens (2-OHE and 4-OHE) to reactive semiquinones and quinones that can directly 
form several types of DNA adduct [190-192]. Moreover, both catechol estrogens and 
their quinone/semiquinone metabolites can indirectly damage DNA and protein through 
redox cycling and generation of reactive oxygen species (ROS) [193-195]. Therefore, 
CYP-mediated estrogen metabolism can lead to the formation of both oxidative DNA 
damage and estrogen DNA adducts, which implies that these estrogen metabolites are 
potential initiators of tumor formation.  
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Experiments on cell transformation, mutagenicity and carcinogenesis have 
suggested that 4-OHE2 is more carcinogenic than 2-OHE2 [193;196-200;200-202]. It 
has been found that 4-OHE2 is a stronger ER agonist than the parental E2, which 
makes this metabolite a potent promoter of tumor formation [203]. Elevated levels of 4-
OH-estrogens have been measured in breast adenocarcinomas [204]. Treatment with 
 
Fig. 1.1 Pathways of oxidative estrogen metabolism. CYP1B1 
catalyzes the oxidation of E2 to catechol estrogen 2-OHE2 and 
4-OHE2. The catechol estrogens are further oxidized to 
semiquinones (E2-2,3-SQ and E2-3,4-SQ) and quinones (E2-
2,3-Q and E2-3,4-Q). GSTP1 catalyzes the conjugation of GSH 
to the estrogen quinones, leading to the formation of 2-OHE2-
4-SG, 2-OHE2-1-SG, and 4-OHE2-2-SG. CYP1B1 
preferentially forms 4-OHE2, and GSTP1 favors the formation 
of 4-OHE2-2-SG and 2-OHE2-4-SG as indicated by the larger 
arrows. (Figure from Hachey D L et al. Cancer Res 2003; 
63:8492-8499)   
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4-OHE2 enhanced adrenal tumor formation in the Syrian hamster [193;200], and 
neonatal exposure to E2, 2-OHE2, and 4-OHE2 induced endometrial carcinomas in 7, 
12, and 66%, respectively, of treated CD-1 mice [202]. 4-OHE2 was reported to 
increase the production of free radicals that cause subsequent hydroxyl radical-
mediated damage to DNA, whereas 2-OHE2 failed to induce oxidative DNA damage, 
possibly due to rapid methylation by COMT [200;201]. A higher 4-OHE2:2-OHE2 ratio 
has been detected in benign and malignant mammary tumors than in adjacent normal 
tissue [198;199]. The 2-hydroxylated estrogen metabolites, when compared with 4-
OHE2, have a faster rate of metabolism by COMT, a more rapid clearance in vivo, and 
possess weaker hormonal potency in estrogen target tissues [205-210]. Moreover, 2-
OHE2 and its methylated metabolite, 2-methoxyestradiol, have actually been shown to 
inhibit breast cancer growth and angiogenesis, both in vivo and in vitro, which may be 
an important reason for the lack of carcinogenicity of 2-OHE2. 
[196;196;197;197;211;212]. Therefore, all of these findings indicate that 4-OHE2 and 
CYP1B1, the main enzyme that catalyzes the formation of 4-OHE2, play an important 
role in breast carcinogenesis.  
O-methylation: The O-methylation of catechol estrogens is catalyzed by COMT, 
an S-adenosylmethionine-dependent methyltransferase enzyme [213]. The COMT 
gene is located on chromosome 22q11 and this enzyme exists in two forms, soluble 
cytosolic COMT, which is the main form of COMT, and membrane-bound COMT 
[213;214]. Recently, COMT has been closely associated with breast cancer. COMT 
inactivates catechol estrogens, the most carcinogenic and genotoxic estrogen 
metabolites, and therefore prevents both direct DNA damage and oxidative genomic 
18 
 
 
 
alterations [190-195]. The monomethylated estrogen metabolites have essentially no 
ER binding affinity, which suggests that COMT mediated O-methylation is a 
detoxification pathway for these catechol intermediates [215;216]. The methylated 
product of 2-OHE2, 2- methoxyestradiol, inhibits the proliferation of several cancer cell 
lines and is among the most potent endogenous inhibitors of angiogenesis, indicating 
that COMT may play a protective role against estrogen-induced breast cancer  
[196;197;217;218].  
Glucuronidation: The superfamily of microsomal UGT enzymes catalyzes the 
conjugation of UDP-glucuronic acid to various endogenous and exogenous aglycones, 
including estrogen [219]. Steroid hormone glucuronidation has been identified in 
several human organs including the breast [220;221]. Glucuronide conjugates of 
estrogens and catechol estrogens are biologically inactive, more polar than the parent 
molecules, and readily excreted in urine and bile [220].  
Sulfonation: Sulfate conjugation (sulfonation) is an important pathway in the 
biotransformation of many hormones, neurotransmitters, and xenobiotic compounds 
[222]. Sulfonation reactions are catalyzed by members of two distinct enzyme 
superfamilies: ⑴  the membrane-bound sulfotransferases, located in the Golgi 
apparatus, that catalyze the sulfonation of proteins, peptides and glycosaminoglycans 
and ⑵  the cytosolic sulfotransferases (SULTs) that metabolize xenobiotics and 
endogenous compounds such as estrogens [223-225]. The SULT superfamily is divided 
into families that are designated by Arabic numerals; SULT family members share at 
least 45% amino acid sequence identity [226]. Each family can then be further 
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subdivided into subfamilies that are designated by capital letters; SULTs in the same 
subfamily share at least 60% amino acid identity. Individual SULT enzymes within 
subfamilies are then identified using Arabic numerals [226-230]. SULTs catalyze the 
transfer of a –SO3 group from the cosubstrate 3'-phosphoadenosine-5'-phosphosulfate 
(PAPS) to the hydroxyl group of sulfonation targets [231].  
Extensive biotransformation of endogenous and exogenous estrogens to 
sulfonated conjugates, especially the most abundant circulating estrogen sulfates, has 
long been recognized as a major route of estrogen metabolism in humans [232]. 
Estrogen sulfonation decreases estrogenic activity by facilitating estrogen excretion and 
blocking ER-mediated activity [233-235]. Estrogen sulfotransferase activity has been 
detected in various human tissues, including liver, small intestine, kidney, uterus, 
adrenal gland, and breast [236-238]. The in situ sulfonation of estrogen in estrogen 
target tissues contributes significantly to estrogen bioavailability in those tissues [239]. 
Several studies have associated SULT activities with breast cancer, although there are 
some contradictory findings [240-244].   
There are mainly three SULTs, SULT1E1 (also known as estrogen 
sulfotransferase), SULT1A1 (as known as phenol-sulfotransferase) and SULT2A1 (also 
known as DHEA sulfotransferase), which can catalyze the sulfonation of E1 and E2 with 
different affinities [224;228;245]. Among the SULTs, SULT1E1 exhibits the highest 
affinity for estrogen, especially the potent E2, and is the only SULT that sulfonates 
estrogen at physiological nanomolar concentrations of the hormone [246-248]. 
SULT1E1 is highly expressed in normal human breast epithelial cells, but its expression 
is often attenuated in breast cancer and malignant breast cancer cell lines [249-251]. 
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SULT1E1 immunoreactivity has been shown to correlate negatively with tumor size and 
to associate significantly with a reduced risk of recurrence or improved prognosis [97]. 
SULT1A1 and, to a lesser extent, SULT2A1 are the main forms of SULT expressed in 
breast tumors [249;252;253]. However, SULT1A1 sulfonates E2 at micromolar 
concentrations; the affinity of SULT1A1 for E2 is about 300-fold lower as compared to 
SULT1E1 [254]. Therefore, SULT1E1 is the primary SULT that regulates the availability 
of estrogens in the breast and consequently affects cell growth, and abnormal 
expression of SULT1E1 may contribute to the development and growth of breast 
carcinomas. This hypothesis has been supported by the finding that forced SULT1E1 
expression in the human breast cancer cell line MCF7 significantly suppressed E2-
stimulated cell proliferation and DNA synthesis, suggesting that breast tumors may 
maximize E2 levels in situ to promote tumor growth by suppressing the expression of 
SULT1E1 [255]. To date, little is known about the regulation of SULT1E1 expression.   
3 MCF10A model 
The MCF10A-derived lineage of human breast epithelial cell lines is a good 
model to study the molecular events that occur during breast cancer progression 
because these cell lines were all derived from a common genetic background and the 
model includes the full spectrum of neoplastic progression and incorporates aspects of 
both indolent preneoplastic diseases to aggressively neoplastic breast epithelial cell 
growth.  
The pathology of breast cancer tumorigenesis is a multistep sequential process 
that begins with the development of hyperplasia, subsequent progression through 
ductal carcinoma in situ (DCIS), and finally malignant invasive carcinoma (Fig. 1.2). In 
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support of this progression model, several studies have demonstrated that the risk for 
later breast carcinoma and the frequency of molecular changes involving cell-cycle 
regulation and apoptosis that are found in malignant invasive cancer are both increased 
during progression in this continuum [256-262].  
 
1) Hyperplasia: Within the mammary gland there is a vascularized fibro-fatty stroma 
supporting a complex network of branching ducts at the end of which is the functional 
unit of the breast, the terminal duct lobular unit (TDLU). It has been shown 
morphologically that most of the benign and malignant epithelial proliferations in the 
breast are derived from the TDLU [263]. The normal TDLU is lined by two cell layers 
consisting of an inner cuboidal epithelium, and an outer myoepithelial cell layer (also 
named the basal layer). These cells form a distinct luminal border around the empty 
space of the breast duct. Any proliferation that results in an increase of more than the 
normal 2 layer system is called hyperplasia [264].  
 
Fig. 1.2 The progression processes of human breast cancer. (Figure adapted from 
Burstein,H.J., et al, N.Engl.J.Med, 350, 1430-1441) 
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Hyperplasia is usually the first step in the progression toward breast cancer and 
it can be further classified as 'typical' (also called usual ductal hyperplasia), including 
mild hyperplasia (2-4 layers of epithelial cells), moderate hyperplasia (4 or more layers 
of epithelial cells) and florid hyperplasia (Fig. 1.3) or 'atypical' [265]. About 60% of 
„typical‟ hyperplasia has ER over-expression in most of the cells compared with normal 
epithelium [266-268]. However, only the atypical hyperplasia (AH) variety is of concern 
for possible breast cancer [269;270].  
 
With florid hyperplasia, the lumen is distended and irregular, and the luminal 
spaces are filled or partially filled with proliferating epithelial cells [271;272]. The 
individual cells vary in size and shape from ovoid to spindle, elongated reniform, but 
with normal chromatin pattern and indistinct nucleoli [271;272]. Florid hyperplasia is 
associated with a 2-fold increased risk of breast cancer compared with the general 
population in the same age pool [256;271]. 
 
Fig. 1.3 Histological features of hyperplasia. Picture adapted from Dawson et 
al [319]. 
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Atypical Hyperplasia 
 
Fig. 1.4 Atypical Hyperplasia. 
Figure adapted from Dawson et 
al [319].  
AH (Fig. 1.4) is an intermediate stage between hyperplasia of the usual type and 
DCIS. Therefore, AH contains cytological and architectural features of both of these 
other stages [273]. For example, AH has distended ducts, a population of relatively 
uniform small- or medium-sized round, cuboidal or polygonal cells, enlarged but evenly 
distributed hyper-chromatic nuclei, marked cellular proliferation and a regular micro-
papillary configuration [273]. Mitoses, particularly abnormal forms, are infrequently seen 
[273].  
AH is considered to be precancerous and can be detected more frequently in 
malignant breasts than in benign breast disease 
[274]. AH lesions have been reported to have an 
increased proliferation and growth advantage 
over normal epithelium, which has been 
attributed to the expression of a mutated, 
estrogen hypersensitive ER [275]. It is clear that 
AH is a rare condition only being seen in 4-5% 
of benign biopsies but it confers a 4-5 time 
increased chance of developing breast cancer when compared with an age-matched 
general population [276;277].   
The specific criteria for distinguishing „typical‟ hyperplasia from AH have been 
well established [256]. „Typical‟ hyperplasia is characterized by cellular variability, 
nuclear overlap, and indistinct cell borders [256].     
2) DCIS: „Typical‟ and „atypical‟ hyperplasia and DCIS have traditionally been 
categorized as intraductal proliferative lesions [276]. After the onset of mammography 
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Ductal Carcinoma in situ 
 
Fig. 1.5 Figure adapted from 
Dawson et al [319].  
Comedo DCIS
Solid with necrosis
DCIS
Cribriform DCIS
Cribriform DCIS 
with necrosis
Micropapillary DCIS
 
Fig.1.6 Comedo, solid, cribriform, and micropapillary ductal carcinoma in situ. 
Picture adapted from Bellamy et al [287]. 
screening, DCIS accounted for about 20% of all breast cancers detected in North 
America [278;279]. DCIS is a pre-invasive malignant proliferation of breast epithelial 
cells and has been demonstrated to be the 
evolutionary origin of invasive cancers because 
both of them present the same chromosomal 
alterations [280;281].  
In this stage (Fig.1.5), ducts are grossly 
distended by tumor cells and the central area 
occasionally shows extensive comedo necrosis. 
DCIS shows a micro-papillary growth pattern and 
forms rigid intraluminal bridges with well-defined round spaces. The epithelial cells of 
DCIS tend to have distinct cell boundaries and become monomorphic. Chromosomal 
imbalance, prominent and multiple nucleoli, and enlarged nuclei are also seen in this 
stage. DCIS lacks evidence for invasion across the basement membrane, which can be 
confirmed by immunohistochemical (IHC) assessment of markers of the myoepithelial 
cell layer and the basement membrane surrounding the ductal lumen [282;282]. 
However, it has been reported that high-grade DCIS is remarkable for the break down 
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Fig. 1.7 Nuclear grading. Picture 
adapted from „Breast Pathology on the 
Web‟ 
of the myoepithelial cell layer and basement membrane surrounding the ductal lumen 
[283].  
The expression profile of genes and proteins that are involved in cell 
proliferation, differentiation, signal transduction, interaction between cells and the 
surrounding extracellular matrix, and intracellular transport has been characterized and 
compared among different stages of breast cancer progression [284;285]. The data 
indicate that most of the critical changes during breast tumorigenesis happen in DCIS 
and prior stages [285]. A recent study showed that high grade DCIS had a greater 
tendency to be HER2 positive and basal-like than lower grade DCIS, which indicates 
that DCIS may be the precursor of basal-
like invasive breast cancer [286].  
It is well accepted that DCIS 
consists of a heterogeneous range of 
lesions with diverse histopathological 
features, genetic alterations, molecular 
biomarkers, and the chance of 
progression to invasive cancer. Various 
systems have been used to classify 
DCIS. The traditional classification is mainly based on architectural growth pattern and 
nuclear grading [287]. According to this system, DCIS can be further classified as 
comedo, solid, cribriform, micropapillary and papillary DCIS [287;288] (Fig. 1.6). 
However, this system provided poor reproducibility and inadequate ability to predict the 
potential for progression to invasive disease. Therefore, numerous updated 
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classification criteria have been proposed mainly based on lesion size, nuclear grading, 
necrosis, calcification, cytonuclear features and molecular bio-markers [289-293]. It is 
important to note that nuclear grading is the single criterion that has been shown to 
associate closely with recurrence after surgical excision of DCIS. As shown in Fig. 1.7, 
nuclei were graded into three levels: 
Low grade: Nuclei are spherical, monotonous in appearance, small and 
centrally placed. Chromatin is finely distributed and mitoses are rare [294]. 
High grade: Nuclei are irregular in shape, pleomorphic, large and varied 
in size. Coarse chromatin, prominent multiple nucleoli and frequent 
mitoses are also commonly found in this level [294]. 
Intermediate grade: Nuclei show features in between those described for 
low and high grade [294].  
In summary, based on the criteria described above, DCIS can be further 
classified into two grades. High grade DCIS is comprised of a group of atypical cells 
with high or intermediate grade nuclei and exhibits several growth and architectural 
patterns, including solid, micropapillary and cribriform. Comedo-type central necrosis 
with calcification is common in this grade. High grade DCIS tends to be ER-negative 
and HER2-positive and contains a series of other genetic changes [295-297]. Low 
grade DCIS contains a population of proliferative monomorphic cells with low grade 
nuclei, and the cells are generally arranged in micropapillary and cribriform patterns. 
This grade of DCIS is frequently ER-positive [298;299].  
Low grade DCIS and AH are morphologically and histologically similar and hard 
to distinguish. However, low grade DCIS is associated with a significantly higher risk of 
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invasive breast cancer development compared to AH [270;271]. Therefore, it is clinically 
important to separate low grade DCIS from AH. The diagnostic distinction between AH 
and DCIS is fundamentally based on the extent of involvement (Fig. 1.8). If the 
proliferative cell amount is limited and does not congest the entire duct space, AH is 
identified [270;276]. DCIS is diagnosed if the cellular proliferation involves two or more 
adjacent duct spaces and is at least 2 mm in aggregate length [300].  
 
3) Invasive breast cancer: Invasive breast cancer is an extremely heterogeneous 
disease in its rate of proliferation, nuclear morphology, stromal response, pattern of 
infiltration, degree of differentiation and clinical course. Different types of carcinoma 
have distinct prognostic outcomes and treatment options [301]. For example, tubular 
carcinoma and papillary carcinoma have a better prognosis compared with invasive 
ductal carcinoma, not otherwise specified [302].  
Thanks to microarray technology, the molecular changes that enable normal 
epithelial cells to progress to invasive, metastatic disease are increasingly well 
understood [303;304] and the gene expression profiles are used to discriminate 
Atypical ductal hyperplasia Ductal carcinoma in situ
 
Fig. 1.8 The diagnostic distinction between atypical ductal hyperplasia 
and ductal carcinoma in situ. Picture adapted from Wiechmann,L. and 
Kuerer, H.M., 2008, Cancer, 112, 2130-2142. 
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different subtypes of breast cancer. According to ER-expression (normally expressed 
by luminal breast epithelial cells), breast cancer can be divided into two groups: ER-
positive and ER-negative [284;303;305]. The risk factors, precursors, clinical behaviors 
and outcomes differ between ER-positive and ER-negative breast cancers [306-311]. 
The ER-negative group can be further subdivided into: basal-like, HER2-positive and 
normal-like tumors [284;303;305]. Basal-like breast cancers, a subtype originating from 
the basal epithelial layer, overlap with the so called triple-negative breast cancer 
(TNBC) (ER-, PR-, and HER2-negative). TNBC has become a focus of intense 
research since TNBC patients have a younger age at onset, higher tumor grade, larger 
tumor size, and increased propensity to develop metastases. Most importantly, they 
lack the three most significant therapeutic markers for clinical management resulting in 
the worst outcome when compared with other cancer subtypes [168;216;306;312;313].  
The MCF10A-derived lineage of human breast epithelial cell lines is a good 
model to study TNBC because the resulting cancer cell lines of this lineage (MCF10CA) 
are triple negative [314;315]. This model mimics the development of human breast 
carcinoma from benign hyperplasia through AH to DCIS and eventually to malignant 
invasive tumors with the potential to metastasize. The parental MCF10A cell line was 
derived from spontaneously immortalized breast epithelial cells that were obtained from 
a donor with benign proliferative breast disease [315]. MCF10A cells are ER negative, 
near diploid and non-tumorigenic because MCF10A cells do not give rise to persistent 
lesions when xenografted into immunodeficient mice [315-317]. The MCF10A cell line 
has been used extensively as a model of normal breast epithelial cells because they 
maintain typical breast epithelial characteristics such as formation of acini in collagen, 
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lack of anchorage-independent growth, and requirement for hormones and growth 
factors to grow in culture [316].  
 
In vitro stable transformation of MCF10A cells with the mutated c-Ha-ras 
oncogene resulted in development of the premalignant MCF10AneoT variant cell line 
that slowly generates simple ductal lesions within 7-8 weeks when xenografted into 
nude mice (Fig. 1.9) [56]. Serial passage of xenograft lesions formed by MCF10AneoT 
cells led to the establishment of preneoplastic MCF10AT1 and MCF10AT1Kcl2 cell 
lines [318]. The MCF10AT1 cell line was established from a 100-day old MCF10AneoT 
squamous carcinoma explant lesion. When xenografted into nude mice, MCF10AT1 
Malignant
Fibrocystic
Breast 
MCF10A
T24 Ras 
Transfection
MCF10
AneoT
MCF10AT1
MCF10A
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Fig. 1.9 The production of MCF10A lineage Human Breast Cancer Cell Lines. 
Figures adapted from [318,319]. The parental MCF10A cell line was derived from 
spontaneously immortalized breast epithelial cells that were obtained from a 
donor with benign proliferative breast disease. In vitro stable transformation of 
MCF10A cells with the mutated c-Ha-ras oncogene resulted in development of 
the premalignant MCF10AneoT cell line. Serial passage of xenograft lesions 
formed by MCF10AneoT cells led to the establishment of preneoplastic 
MCF10AT1 and MCF10AT1Kcl2 cell lines. A 292-day old MCF10AT1Kcl2 
xenograft that progressed to adenocarcinoma was the source of the malignant 
MCF10CA variant series after serial passage of humor pieces. The 
MCF10DCIS.com cell line was developed by cloning of one of the malignant 
variants, MCF10CA1h     
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cells produced a spectrum of preneoplastic lesions, including AH and DCIS [317]. 
MCF10AT1 cells demonstrate a ~25% incidence of invasive cancers in xenograft 
lesions that develop over an extended period of time [319]. The MCF10AT1Kcl2 cell 
line was established from a 367-day old MCF10AneoT adenocarcinoma xenograft 
lesion. The MCF10AT1K.cl2 variant retained an MCF10AT1-type pattern of xenograft 
growth but also displayed chromosomal aberrations more characteristic of genetic 
instability and could form hyperplastic lesions more rapidly [318].  
A 292-day old MCF10AT1Kcl2 xenograft that progressed to adenocarcinoma 
was the source of the malignant MCF10CA variant series after serial passage of tumor 
pieces. Rather than forming simple ducts, MCF10CA variants rapidly form highly 
proliferative invasive carcinomas at an incidence of 100% [318]. The MCF10DCIS.com 
cell line was developed by cloning of one of the malignant variants, MCF10CA1h [320]. 
MCF10CA1h was derived from a lesion formed by two successive trocar passages of a 
lesion formed by premalignant MCF10AT cells. Injection of MCF10DCIS.com cells into 
immunodeficient mice produces rapidly growing lesions that are consistent with the 
poor prognosis comedo-type DCIS and invariably  progress to invasive cancer [320].  
4.    Statement of problem 
Despite a growing understanding of SULT1E1‟s function in steroid hormone and 
drug metabolism, the role of SULT1E1 in the malignant progression of breast epithelial 
cells is still unknown. We previously reported that SULT1E1 mRNA was expressed in 
the “normal” breast epithelial MCF10A cells and in the preneoplastic MCF10AT1 and 
MCF10AT1Kcl2 cell lines [250]. However, the expression was “switched off” in the more 
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neoplastically progressed variant cell lines, beginning with the MCF10CA1a cell line 
[250]. Thus, MCF10AT1 cells that have preserved SULT1E1 expression and E2-ER 
regulated growth can be used to determine the impact of SULT1E1 expression on 
tumorigenicity. In the same study, we observed a proliferation state-dependent 
expression of SULT1E1 in MCF10A cells [250]. Therefore, the regulatory mechanism 
for this phenomenon was also investigated. 
The results of this research will provide new information on the role of SULT1E1 
in breast cancer progression. Since SULT1E1 has high affinity for physiological 
concentrations of estrogen, SULT1E1 may represent a good target for the prevention 
and treatment of breast cancer in humans.  
Chapter 2 of the dissertation discusses the expression of estrogen-metabolizing 
genes including cytosolic sulfotransferases (SULT1E1, SULT1A1, SULT2A1, and 
SULT2B1), STS, CYP19, 17β-hydroxysteroid dehydrogenases (17βHSD1 and 2), 
CYP1B1, and catechol-O-methyltransferase (COMT) in the MCF10A-derived lineage 
cell culture model for basal-like human breast cancer progression and in ERα-positive 
luminal MCF7 breast cancer cells. Chapter 3 delineates the role of the aryl hydrocarbon 
receptor (AhR) in the transcriptional regulation of SULT1E1 in the non-tumorigenic 
MCF10A cell line. In chapter 4, the mechanism underlying tobacco smoke condensate 
(TSC)-mediated down-regulation of SULT1E1 expression in MCF10A cells is 
discussed. In chapter 5, the impact on tumorigenesis of SULT1E1 knock-down in the 
MCF10AT1 xenograft model is presented.  
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CHAPTER 2 
 
Expression of estrogenicity genes in a lineage cell culture model 
of human breast cancer progression 
 
INTRODUCTION 
The estrogen sensitive nature of breast cancer was observed by Beatson over 
100 years ago [321]. Prolonged cumulative exposure to estrogen during a woman‟s 
lifetime is a significant risk factor for the development of breast cancer [322]. Estrogen 
stimulates cell growth through ER-mediated events, which can enhance opportunities 
for DNA mutation. In addition, reactive estrogen metabolites generated by cytochrome 
P450-mediated catalysis, such as estrogen catechols and quinones, can directly induce 
mutations [167]. Particularly in post-menopausal women who lack ovarian sources of 
estrogen, the factors that govern intra-tissue metabolism of biologically active estrogen 
(i.e., estrogen “intracrinology”) are important therapeutic targets and biomarkers for 
breast cancer progression [323]. Determinants affecting the amount and activity of 
estrogen in breast tissue include expression of the major forms of estrogen receptor 
(ERα and ERβ), cytosolic sulfotransferases (SULTs), STS, CYP19, 17β-hydroxysteroid 
dehydrogenase types 1 and 2 (17βHSD1 and 17βHSD2), CYP1B1, and COMT (Fig. 2.1 
adapted from [246;324;325]).  
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This study, published in Breast Cancer Research and Treatment [250], was 
designed to elucidate the expression of determinants of estrogen activity in MCF10A 
derived lineage cell culture model that captures the heterogeneity of breast cancer 
progression in humans.  
 
Fig. 2.1 Pathways of estrogen metabolism, bioactivation, and action. 
CYP19 (aromatase) catalyzes the aromatization of androstenedione and 
testosterone to form estrone (E1) and 17β-estradiol (E2), which can bind to and 
activate ER. Of the cytosolic SULTs, SULT1E1 preferentially catalyzes the 
sulfonation of E1 and E2 with high efficiency. Sulfonated estrogens are ER-
inactive. Steroid sulfatase (STS) catalyzes the deconjugation of sulfonated 
steroids and favors the formation of biologically active estrogen. STS and 3-β-
hydroxysteroid dehydrogenase (3βHSD isomerase) function in the formation of 
sex steroids from precursor hormones, such as dehydroepiandrosterone sulfate 
(DHEA sulfate) and dehydroepiandrosterone (DHEA). 17βHSD1 reduces E1 to 
the more potent E2, while 17βHSD2 oxidizes E2 to E1. The 4-hydroxylation of 
E2 is catalyzed by CYP1B1; E2 2-hydroxylation is catalyzed by CYP1A1. 
Catecholestrogens auto-oxidize to form mutagenic orthoquinone electrophiles 
that can be detoxified via COMT-mediated conjugation. 
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The molecular phenotypic characteristics of the MCF10A lineage indicate that 
this is a model of basal breast cancer, in that the resulting MCF10CA1 cancer cell lines 
are triple negative (i.e., do not express ER, PR or HER2/neu) [314;315]. Nevertheless, 
xenograft studies have demonstrated that progression of preneoplastic MCF10AT1 
cells is sensitive to estrogen manipulation [319;326-328]. Estrogen has been shown to 
alter signal transduction in triple negative MDA-MB-231 (do not express ERα; do 
express ERβ) and SKBR3 cells (express neither ERα nor ERβ), causing activation of 
the extracellular signal regulated kinases, ERK1 and ERK2 [147]. Both estrogen and 
EGF induced phosphorylation of c-raf and ERK1/2 while stimulating the proliferation of 
SKBR3 cells [329], and the two agents were more effective in combination. Importantly, 
growth of ERα-negative breast cells was induced by the same 17β-estradiol (E2) 
concentration (10
−9
 M) that stimulates ERα-positive MCF7 cells, whereas a higher 
concentration (10
−6
 M) inhibited the growth of MDA-MB-231, and SKBR3 cells, and this 
inhibition was additive with heregulin [330].  
Although MCF7 requires supplementation with E2 to mimic pre-menopausal 
human serum levels (typically 400–1,500 pg/ml) to achieve xenograft growth in nude 
mice, MCF10AT1 forms lesions that progress to atypical hyperplasia, DCIS and 
invasive ductal carcinoma without E2 supplementation. Serum E2 levels in nude mice 
are typically less than 50 pg/ml [331], which mimics post-menopausal human serum 
levels [332]. However, MCF10AT1 cells form lesions consisting only of simple ducts in 
ovariectomized (OVX) nude mice [333], which have serum E2 levels of ~5 pg/ml [334]. 
Therefore, MCF10AT1 xenografts respond to very low doses of E2 in vivo, suggesting 
that the levels of estrogen-processing enzymes in breast cells may play a critical role in 
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determining growth response. Therefore, an analysis of the determinants of 
estrogenicity in MCF10A lineage cell lines was undertaken to provide insight into the 
dynamic changes in estrogen responsiveness that occur during basal breast cancer 
development.  
Histone deacetylases (HDACs) are being increasingly recognized for their 
important roles as transcriptional modulators of pro-survival pathways during breast 
cancer progression [335]. HDAC inhibitors, such as Vorinostat, Valproic acid, and 
Panobinostat, are currently tested in many phase I and II clinical trials as single agents 
as wells as in combination schemes in the treatment for breast cancer. They have 
demonstrated to have promising antitumor activity, favorable clinical effects and, most 
importantly, encouraging activity in reversing hormone resistance [336-339]. However, 
their effects on the expression of estrogen metabolism machinery during breast cancer 
progression are unknown. Therefore, the effects of treatment with trichostatin A (TSA), 
a potent HDAC inhibitor, on ER and estrogen metabolism gene expression in the 
MCF10A lineage cell lines were also investigated.  
 
Materials and methods 
 
Materials. TaqMan Gene Expression reagents were purchased from Applied 
Biosystems (Foster City, CA). qPCR Human Reference Total RNA was purchased from 
Clontech Laboratories (Mountain View, CA). Culture media, sera, L-glutamine, sodium 
pyruvate, penicillin-streptomycin, anti-SULT1E1 antibody, recombinant human 
SULT1E1, Superscript II, and Lipofectamine 2000 were purchased from Invitrogen 
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Corporation (Carlsbad, CA). EGF was purchased from BD Biosciences (San Jose, CA). 
Recombinant human insulin (Novolin R) was purchased from Novo Nordisk 
Pharmaceuticals, Inc. (Princeton, NJ). Cholera toxin, hydrocortisone and TSA were 
purchased from Sigma–Aldrich (St. Louis, MO). Horseradish peroxidase-conjugated 
goat anti-rabbit IgG was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
ECL Plus Western Blotting Detection Reagents and Hybond-P membranes were 
purchased from GE Healthcare (Piscataway, NJ). Other materials were obtained from 
the sources indicated below.  
Cell culture. MCF7 and MCF10A lineage (MCF10A, MCF10AT1, MCF10AT1K.cl2, 
MCF10CA1a, MCF10CA1d and MCF10DCIS.com) cell lines were obtained from the 
Cell Resources Facility of the Barbara Ann Karmanos Cancer Institute, Wayne State 
University. MCF10A lineage cell lines were cultured in phenol red-free Dulbecco‟s 
Modified Eagle Medium/Ham‟s F12 (DMEM/F12) nutrient mixture (1:1) supplemented 
with 10 μg/ml insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone, 
5% horse serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. MCF7 cells were 
cultured in phenol red-free Minimum Essential Medium supplemented with 10 μg/ml 
insulin, 1 mM sodium pyruvate, 10% calf serum, 100 U/ml penicillin, and 100 μg/ml 
streptomycin. Cell lines were routinely maintained in T75 flasks in a 37°C humidified 
environment of 5% CO2/95% air. For experiments, 250,000 cells were plated into 
60 mm dishes. For pre-confluent cultures (~70% confluency), cells were harvested 
2 days after plating. Confluency was reached approximately 5 days after plating. On 
day 7, confluent cultures were harvested for preparation of total RNA. Experiments 
were conducted at a cell density of 70% confluency unless otherwise indicated. For 
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TSA studies, 24 hr after plating, cells were treated with 0.1% dimethyl sulfoxide (DMSO 
control) or TSA.  
TaqMan Gene Expression assays. Total RNA was prepared from individual dishes of 
cells using the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA samples were reverse 
transcribed using Superscript II. Transcript levels were measured using the following 
TaqMan Gene Expression Assays: Hs01046818_m1 (ERα), Hs00230957_m1 (ERβ), 
Hs00193690_m1 (SULT1E1), Hs00419411_m1 (SULT1A1), Hs01105284_m1 
(SULT2B1), Hs00234219_m1 (SULT2A1), Hs00165853_m1 (STS), Hs00240671_m1 
(CYP19), Hs00166219_g1 (17βHSD1), Hs00157993_m1 (17βHSD2), Hs00164383_m1 
(CYP1B1), and Hs00241349_m1 (COMT). Each PCR reaction included 2 μl of cDNA 
template, a primer/probe (5-carboxyfluorescein fluor, minor groove binder quencher) set, 
a primer-limited primer/probe (VIC-minor groove binder) set for 18S rRNA and Universal 
PCR master mix, and amplifications were performed using an ABI Prism 7500 
Sequence Detection System. Thermocycling parameters were 94°C for 10 min, and 
40 cycles of 95°C for 15 s and 60°C for 1 min. Cycle threshold (Ct) values were 
obtained using the SDS software package. For each sample, ΔCt was obtained by 
subtracting the Ct of 18S rRNA from the Ct of target mRNA. Then, ΔΔCt values were 
calculated by subtracting the ΔCt of the calibrator to which the other samples were 
compared from the ΔCt of each sample. Mean relative quantitative expression values 
were then calculated as 2
 −ΔΔCt
.  
Western blot and enzyme activity analyses. Cells in T75 flasks were washed with 
and scraped into ice-cold phosphate-buffered saline (PBS). Cells were pelleted and 
homogenized by sonication in buffer (200 μl per flask) consisting of 50 mM Tris–HCl, 
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25 mM sucrose, 1 mM EDTA and 1× Halt protease inhibitor (Thermo Fisher Scientific, 
Rockford, IL), pH 7.4. Homogenates were centrifuged at 20,000×g at 4°C for 20 min, 
and supernatants were used for western blot analysis. Protein concentrations were 
measured using the BCA Protein Assay (Thermo Fisher). Western blot analysis of 
SULT1E1 content was accomplished as described previously [340], using 30 μg of 
sample protein and polyclonal anti-SULT1E1 antibody. Uniform protein loading and 
transfer were verified using Ponceau S staining. SULT1E1 catalytic activity was 
measured in whole cell lysates prepared from MCF10CA1a cells as described [341].  
Transient transfection analysis. The p2ERE-luc reporter was constructed by ligating 
a double-stranded oligonucleotide containing two vitellogenin ERE upstream of a 
minimal herpes simplex virus thymidine kinase promoter, which had been preligated 
into pGL3-Basic (Promega Corporation, Madison, WI). The sequences of the 
oligonucleotides are: 5′-CGCGTGTCCAAAGTCAGGTCACAGTGACCTGATTCAGGTC 
ACAGTGACCTGATCAAAGTTA-3′ and 5′-GATCTAACTTTGATCAGGTCACTGTGACC 
TGAATCAGGTCACTGTGACCTGACTTTGGACA-3′.  
MCF7 cells (400,000) were seeded into 12-well plates and cultured in 2 ml 
phenol red-free Minimum Essential Medium supplemented with 10 μg/ml insulin, 1 mM 
sodium pyruvate and 10% charcoal-stripped fetal bovine serum. The following day, 
Opti-MEM containing a premixed complex of 4 μl of Lipofectamine 2000, 1.6 μg 
p2ERE-Luc and 1.25 ng pRL-SV40 (Promega) was added to each well. The following 
day, cultures (5 wells per group) were incubated with phenol red-free Minimum 
Essential Medium, supplemented as described above, containing 0.1% DMSO, 10 nM 
E2, 300 ng/ml TSA, or E2 and TSA in combination. After 48 hr, the cells were harvested 
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Fig. 2.2 Expression of SULT1E1 mRNA and protein in the MCF10A-derived 
lineage cell culture model for breast cancer progression and in MCF7 cells. 
A: A TaqMan Gene Expression assay was used to determine the relative levels of 
SULT1E1 mRNA in subconfluent (70%, white bars) and confluent (100%, black 
bars) MCF10A series cells (from left to right, MCF10A, MCF10AT1, 
MCF10AT1K.cl2, MCF10CA1a, MCF10CA1d and MCF10DCIS.com) and in 
MCF7 cells. SULT1E1 mRNA content is expressed relative to the level measured 
in subconfluent MCF10A cells, and all values represent the mean ± SEM of three 
independent cell culture experiments. Groups labeled with different letters are 
significantly different from each other (P < 0.05). B:  Representative Western 
blots showing the relative amounts of SULT1E1 immunoreactive protein in 
subconfluent MCF10A-derived cell lines.  
 
 
for measurement of firefly and Renilla luciferase activities using the Dual Luciferase 
Reporter Assay System (Promega) and a Dynex model MLX Luminometer.  
Statistical analysis. Data were analyzed using the paired t-test or one-way analysis of 
variance followed by the Newman–Keuls test using Prism (GraphPad Software, San 
Diego, CA).  
Results 
 
The high catalytic efficiency of SULT1E1 toward E2 sulfonation supports a major 
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role for SULT1E1 in the in situ inactivation of E2 within the breast. SULT1E1 mRNA 
was detected in parental MCF10A cells, although the level of expression was highly 
dependent upon the confluency of the cultures. Relative to pre-confluent MCF10A cells, 
the amount of SULT1E1 mRNA in confluent cells was significantly increased by ~16-
fold (Fig. 2.2A). SULT1E1 mRNA expression was robust in MCF10AT1 cells, and unlike 
MCF10A cells, was not significantly affected by confluency (Fig. 2.2A). SULT1E1 
mRNA expression was also substantial in MCF10AT1K.cl2 cells, but was markedly 
diminished in MCF10CA1a, MCF10CA1d, MCF10DCIS.com, and MCF7 cells 
(Fig. 2.2A). SULT1E1 immunoreactive protein levels in the MCF10A lineage cell lines 
were in accord with the corresponding mRNA levels (Fig. 2.2B). Since STS and other 
cytosolic SULTs have been implicated in the modulation of breast intracrinology 
[79;97;254;341-343], the expression patterns of STS and SULTs 1A1, 2A1, and 2B1 
were characterized. STS mRNA was detected across the MCF10A series cell lines, as 
well as in MCF7 cells (Fig. 2.3A). SULT1A1 and SULT2B1 transcripts were detected 
only in MCF7 cells, while the mRNA for SULT2A1, an enzyme that is highly expressed 
in human liver and adrenal gland [342], was not detected in any of the breast cell lines 
(Fig. 2.3B). 17βHSD1 catalyzes the reduction of estrone (E1) to the more potent E2, 
while 17βHSD2 catalyzes the oxidation of E2 to E1 [344]. 17βHSD1 mRNA was 
detected in all cell lines but was highest in the MCF10CA1a and MCF10DCIS.com cells 
(Fig. 2.3B). By contrast, 17βHSD2 mRNA was expressed most abundantly in the 
parental MCF10A cell line (Fig. 2.3B).   
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Fig. 2.3 Expression of estrogen metabolism enzymes in MCF10A series and 
MCF7 cell lines. TaqMan Gene Expression assays were used to determine the 
relative levels of STS, SULT1A1, SULT2B1, SULT2A1 (A), 17βHSD1, 17βHSD2 (B), 
CYP19, CYP1B1, and COMT (C) mRNA in pre-confluent MCF10A series cell lines 
and in MCF7 cells. The mRNA levels are expressed relative to their respective levels 
in MCF10A cells, MCF7 cells or a human RNA reference pool (HRP). All values 
represent the mean ± SEM of three independent cell culture experiments. For all 
transcripts except 17βHSD2 and CYP1B1: Groups labeled with different letters are 
significantly different from each other (P < 0.05). For 17βHSD2 and CYP1B1: 
*** Significantly different from all other groups, P < 0.001. When the group labeled 
with *** was omitted from the analyses, groups labeled with different letters are 
significantly different from each other (P < 0.05). For STS and COMT, no significant 
differences among groups were detected. For SULT2A1 and CYP19, mRNA levels 
were undetected in all cell lines.  
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Fig. 2.4 ERα and ERβ mRNA expression in pre-
confluent MCF10A series and MCF7 cell lines. 
TaqMan Gene Expression assays were used to 
determine the relative levels of ERα (top) and ERβ 
(bottom) mRNA. The mRNA contents of ERα and 
ERβ are expressed relative to their respective levels 
in MCF10A cells, and all values represent the 
mean ± SEM of three independent cell culture 
experiments. For ERα, groups labeled with different 
letters are significantly different from each other 
(P < 0.05). For ERβ, no significant differences among 
groups were detected. 
 
 
 
The transcript for CYP19, which catalyzes the aromatization of androstenedione 
and testosterone to E1 and 
E2, respectively [345], was 
not detected in any cell line 
(Fig. 2.3C). CYP1B1 is the 
most active E2 hydroxylase 
[346], and high levels of E2 
hydroxylation in estrogen-
responsive tissues may play 
an important role in 
estrogen-related 
tumorigenesis [177]. By 
contrast, O-methylation 
catalyzed by COMT is an 
inactivation pathway for E2 
catechols and quinones 
[177]. CYP1B1 mRNA levels 
were highest in MCF7 cells 
(Fig. 2.3C). Though 
CYP1B1 mRNA also appeared to be higher in MCF10AT1 and MCF10AT1K.cl2 cells 
than in the other MCF10A series cells (Fig. 2.3C), this difference was not maintained 
when the cultures were treated with DMSO (experiment shown in Fig. 2.6). COMT 
demonstrated relatively consistent mRNA expression across cell lines (Fig. 2.3C).  
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Fig. 2.5 Effects of TSA treatment on ERα and ERβ mRNA expression in 
MCF10A series and MCF7 cell lines and on E2-mediated activation of an 
estrogen-responsive reporter gene. a Cell lines were treated for 24 h with 0.1% 
DMSO (white bars) or 300 ng/ml TSA (black bars), and ERα and ERβ mRNA levels 
were measured with TaqMan Gene Expression assays. ERα and ERβ mRNA levels 
are expressed relative to the amounts measured in DMSO-treated MCF10A cells. 
All values represent the mean ± SEM of three independent cell culture experiments. 
*, ** Significantly different from the corresponding DMSO-treated group, P < 0.05 
and P < 0.01, respectively. b MCF7 cells were transiently transfected with an 
estrogen-responsive luciferase reporter plasmid. After transfection, cells were 
treated with 0.1% DMSO, 10 nM E2, 300 ng/ml TSA, or E2 and TSA in combination 
for 48 h. After treatment, cells were harvested for the measurement of luciferase 
activities. Each bar represents the mean ± SEM of normalized (firefly/Renilla) 
luciferase measurements (5 wells per treatment group) relative to the activity 
measured in DMSO-treated cells. ** Significantly different from the E2-treated group 
P < 0.01 
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ER expression is a major determinant of estrogenic activity. As expected, the 
ER-positive MCF7 cell line expressed ERα mRNA at a level that was >100-fold greater 
than that detected in any of the MCF10A series cell lines (Fig. 2.4). ERα 
immunoreactive protein is reportedly undetectable in MCF10A cells [314], and in the 
present study ERα mRNA was detected at a low level in the MCF10A lineage cells 
(Fig. 2.4). By comparison, ERβ mRNA levels were not abundant either in MCF7 cells or 
in the MCF10A-derived series of cell lines (Fig. 2.4). 
Since HDACs are important modulators of transcription and therapeutic targets 
in breast cancer [335;339], the effects of TSA treatment were characterized on ER and 
estrogen metabolism enzyme expression. As previously reported [347], TSA treatment 
of MCF7 cells produced a dramatic decrease (>99%) in ERα mRNA expression 
(Fig. 2.5A). The loss of E2 agonistic activity following TSA treatment was confirmed 
using an ER-responsive reporter (Fig. 2.5B). By contrast, TSA treatment increased ERβ 
mRNA levels in MCF7 cells by ~11-fold (Fig. 2.5A). TSA produced less pronounced 
effects on ERα and ERβ mRNA expression in the MCF10A lineage cell lines 
(Fig. 2.5A). 
TSA also produced marked alterations in the mRNA expression of estrogen 
metabolism enzymes in the cell lines. In the neoplastic MCF10CA1a cell line, where 
SULT1E1 mRNA expression is substantially suppressed, TSA treatment produced a 
concentration-dependent increase in SULT1E1 mRNA expression that correlated with 
the induction of E2 sulfonation activity (Fig. 2.6A). TSA treatment increased SULT1E1 
mRNA content by at least two-fold (2.3- to 26.1-fold) in all MCF10A series cell lines 
except MCF10AT1, although the increase was statistically significant only for 
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MCF10DCIS.com (Fig. 2.6B). TSA treatment also activated CYP19 expression in all of 
the cell lines (Fig. 2.6C). By contrast, TSA treatment uniformly suppressed STS and 
COMT expression (Fig. 2.6C). TSA treatment produced marked suppression of 
SULT1A1, SULT2B1 and CYP1B1 mRNA levels in MCF7 cells, while SULT2A1 
expression was induced in TSA-treated MCF7 cells (Fig. 2.6C). TSA treatment also 
suppressed 17βHSD1 and 17βHSD2 expression in the MCF10A series cell lines that 
demonstrated constitutive expression (Fig. 2.6C).  
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Fig. 2.6 TSA treatment effects on estrogen metabolism enzyme expression in MCF10A 
series and MCF7cell lines. A: Concentration-dependent effects of TSA treatment on 
SULT1E1 mRNA expression in MCF10CA1a cells. MCF10CA1a cells were treated for 24 h 
with 0.1% DMSO or with 75, 150 or 300 ng/ml TSA and harvested for measurement of 
SULT1E1 mRNA levels with a TaqMan Gene Expression assay. All values represent the 
mean ± SEM of three independent cell culture experiments relative to the amount measured 
in the DMSO-treated cells. *** Significantly different from the DMSO-treated group, 
P < 0.001. Inset Correlation of TSA-mediated changes in SULT1E1 enzymatic activity with 
changes in SULT1E1 mRNA levels. B: MCF10A series and MCF7 cell lines were treated for 
24 h with 0.1% DMSO or 300 ng/ml TSA and SULT1E1 mRNA levels were measured. 
SULT1E1 mRNA contents are expressed relative to the level measured in DMSO-treated 
MCF10A cells. All values represent the mean ± SEM of three independent experiments. 
* Significantly different from the corresponding DMSO-treated group (P < 0.05). C: Cells 
were treated as indicated in B and estrogen metabolism enzyme mRNA levels were 
measured. STS, COMT, CYP1B1, 17βHSD1, and 17βHSD2 mRNA contents are expressed 
relative to the respective levels measured in DMSO-treated MCF10A cells. SULT1A1 and 
SULT2B1 mRNA levels are expressed relative to the levels measured in DMSO-treated 
MCF7 cells. SULT2A1 mRNA levels are expressed relative to the level measured in TSA-
treated MCF7 cells. CYP19 mRNA levels are expressed relative to the level measured in 
TSA-treated MCF10A cells. All values represent the mean ± SEM of three independent 
experiments. *, ** Significantly different from the corresponding DMSO-treated group, 
P < 0.05 and P < 0.01, respectively 
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Discussion 
 
Selective ER modulators, selective ER down-regulators and inhibitors of 
estrogen-producing enzymes, such as CYP19, STS, and 17βHSD1, represent 
important classes of drugs for achieving estrogen blockade in the treatment of 
hormone-responsive breast cancer [348-352]. In addition, HDAC inhibitors, which have 
been shown to down-regulate ERα mRNA expression in MCF7 cells [347], are being 
tested in phase II clinical trials that include patients with ER-positive metastatic breast 
cancer progressing on endocrine therapy [336]. The combination of HDAC inhibitor and 
tamoxifen were associated with low toxicity and reversed hormone resistance [336]. 
Despite an expanded range of targeted therapies, the critical alterations in breast 
intracrinology that predispose patients to breast cancer development remain to be 
elucidated.  
In mammary tissue, stringent control of the powerful mitogen E2 is achieved 
through the tight balance of ERα and ERβ expression coupled with titration of E2 levels. 
Compared to ERβ, ERα is a high affinity receptor for estrogen [353]. Both ERα and ERβ 
bind to the same response elements but produce differential effects on target gene 
expression [354]. ERα is a recognized marker for E2-stimulated proliferation in breast 
cancer [355]. Although further studies are needed to better assess the role of different 
ERβ isoforms, emerging studies have associated ERβ with more aggressive breast 
cancer types and poor clinical outcome [356-358]. In the present study, ERα expression 
in the MCF10A lineage cell lines was low in comparison to its level in MCF7 cells, while 
ERβ mRNA expression was comparably low among the cell lines. As previously 
48 
 
 
 
reported [347], TSA suppressed ERα and induced ERβ expression in MCF7 cells. 
However, TSA produced only modest effects on ERα and ERβ expression in the 
MCF10A series of cell lines.  
The pro-estrogenic machinery of the breast includes STS, CYP19, and 
17βHSD1 [345;359]. Increased expression of STS occurs in 74% of breast cancer 
biopsies and its presence correlates with an adverse prognosis [97]. In the present 
analysis, STS mRNA levels were comparably detected across the MCF10A series of 
cell lines and in MCF7 cells, and TSA treatment consistently tended to repress STS 
expression.  
CYP19 expression in breast tumor tissue facilitates a highly concentrated 
estrogen micro-environment. Like STS, elevated CYP19 expression in breast tumor 
tissue impairs prognosis [325]. Though CYP19 is more robustly expressed in breast 
stroma, the application of fine resolution techniques has revealed the presence of 
CYP19 in normal breast ductal epithelial cells and breast cancer cells, as well as in 
intra-tumor stromal cells and peri-tumoral adipose tissue [360]. In the absence of TSA 
treatment, CYP19 mRNA was not detected in MCF10A series cell lines or MCF7 cells. 
In contrast to a previous report demonstrating a repressive role for TSA on CYP19 
expression in MCF7 cells [361], this investigation revealed a TSA-inducible effect on 
CYP19 expression in all of the cell lines examined.  
There are at least fifteen 17βHSD enzymes that vary in catalytic range and 
efficiency [362]. 17βHSD1 and 17βHSD2 are involved in the interconversion of E2 with 
the less potent E1 [344]. Increased 17βHSD1 expression in breast cancer, either alone 
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or in combination with CYP19, enhances estrogen concentrations and negatively 
impacts prognosis [78;363], as does loss of 17βHSD2 expression [364]. In the present 
study, the mRNA expression of pro-estrogenic 17βHSD1 was detected in MCF10A cells 
but was more abundant in the neoplastic MCF10CA1a and MCF10DCIS.com variants. 
By contrast, 17βHSD2 mRNA was most prominent in parental MCF10A cells. TSA 
treatment produced only suppressive effects on 17βHSD1 and 17βHSD2 expression.  
SULT1E1 is considered to be the predominant E2-inactivating enzyme in breast. 
A previous survey of cytosolic SULT expression concluded that human mammary 
epithelial cells expressed mainly SULT1E1, while breast cancer cell lines preferentially 
expressed SULT1A1 and only trace amounts of SULT1E1 and SULT2A1 [249]. In an 
independent study, SULT1E1 expression was reported in approximately 44% of human 
breast cancer biopsy specimens [97]. The present investigation revealed SULT1E1 
mRNA expression in confluent MCF10A cells and in the preneoplastic MCF10AT1 and 
MCF10AT1K.cl2 cell lines. By contrast, SULT1E1 expression in the more neoplastically 
transformed MCF10A-derived cell lines and in MCF7 cells was markedly repressed. As 
previously described for CYP1A2 expression in MCF10A cells [365], SULT1E1 mRNA 
levels were more abundant in confluent than in proliferating MCF10A cultures. The 
constitutive expression of other steroid-metabolizing SULTs (i.e., SULT1A1, SULT2A1, 
and SULT2B1) was not a prominent feature across the MCF10A-derived cell lines.  
4-Hydroxylated estrogen metabolites produced by CYP1B1 metabolism are 
particularly reactive and considered to be promutagenic [366]. CYP1B1 mRNA and 
protein expression has been reported in up to 73% of human breast cancer biopsies 
[367]. Increased CYP1B1 expression, coupled with the reduced expression of the 
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detoxicating enzyme COMT, is associated with amplified breast cancer risk [366]. In the 
current analysis, CYP1B1 mRNA was present at relatively low levels in the MCF10A-
derived cell lines, but was more abundant in MCF7 cells, where its constitutive 
expression has been previously described [368]. In contrast to a previous report 
suggesting a stimulatory effect of TSA treatment on CYP1B1 expression in MCF7 cells 
[369], the present study revealed TSA-mediated suppression for both CYP1B1 and 
COMT in MCF7 cells. In contrast to the relatively restricted expression of CYP1B1, 
COMT mRNA was widely detected across cell lines.  
In aggregate, it appears that normal or early preneoplastic breast epithelial cells 
act to minimize the mitogenic effects of E2 by retaining the expression of SULT1E1, a 
major E2- inactivating enzyme, and by preserving the expression of the anti-estrogenic 
dehydrogenase, 17βHSD2. Particularly in the MCF10A lineage model for breast cancer 
progression where ERα levels are held to a minimum, the expression of key E2-
metabolizing enzymes is crucial for the establishment of the breast intracrine 
environment. Within the progression model, the expression of pro-estrogenic STS and 
17βHSD1 is maintained, while the capacity for in situ estrogen production through 
aromatization is restrained. Based on the current study, several positive aspects of 
HDAC inhibitor treatment in humans might be anticipated. These include the up-
regulation of SULT1E1 in neoplastic breast epithelial cells and also down-regulation of 
pro-estrogenic metabolic enzymes such as STS and 17βHSD1. With HDAC inhibition, 
the prominent expression of CYP1B1 that is observed in MCF7 cells becomes down-
regulated. However, as a counter-weight, the expression of the protective enzyme 
COMT also becomes down-regulated.  
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The results of this study demonstrate that established breast cancer cell lines, 
such as MCF7, do not necessarily reflect the changes in estrogen metabolism that 
occur in breast epithelial cells as they progress from benign proliferative breast disease 
toward neoplasia. In order to harness the promise and potential power of combined or 
sequential metabolically-targeted therapies in breast cancer intervention, it will be 
become essential to understand and control the real-time dynamics that determine the 
delicate balance of intracrine metabolism within the breast.  
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CHAPTER 3 
 
Regulation of SULT1E1 expression by confluency of MCF10A breast epithelial 
cells: Role of the AhR 
 
INTRODUCTION 
 
The SULTs are a family of conjugating enzymes that catalyze the transfer of a 
sulfuryl moiety from the activated physiological sulfate donor 3'-phosphoadenosine-5'-
phosphosulfate to the hydroxyl groups of endogenous and xenobiotic substrates, 
including hormones, drugs, and procarcinogens [228;370]. One of the SULTs, 
SULT1E1, catalyzes the sulfonation of estrogen at physiological concentrations. 
SULT1E1 is an important determinant of a cell‟s response to estrogen because 
sulfonated estrogen cannot bind to ERs [371]. In this manner, SULT1E1 expression in 
breast epithelial cells likely limits the mitogenic effects of estrogen, thereby reducing the 
risk for breast cancer development [341]. SULT1E1 is expressed in human breast 
epithelial cells as well as in the MCF10A cell line, a model of normal human breast 
epithelial cells, but is down-regulated in many breast cancer cell lines, suggesting that 
this brake against estrogen mitogenicity is lost during neoplastic transformation 
[250;341]. 
During the characterization of estrogenicity gene expression in MCF10A lineage 
cell lines (Chapter 2), we observed that SULT1E1 mRNA content is markedly increased 
when replicating MCF10A cells become confluent (Fig. 2.2) [250], indicating that 
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SULT1E1 expression is regulated according to the confluency of these cells. By 
comparison, in an earlier study in which the expression of cytochrome P450 transcripts 
was profiled in MCF10A cells, two P450s, CYP1A1 and CYP1S1, were expressed in 
pre-confluent MCF10A cells but not in confluent MCF10A cells [365]. Since both of 
these P450s are transcriptional targets of the AhR [372], this finding suggests that AhR 
is active in pre-confluent MCF10A cells but inactive in confluent MCF10A cells. 
AhR agonist treatments cause suppression of SULTs in hepatic systems. 
Treatment of female rats with 3-methylcholanthrene caused suppression of hepatic 
hydroxysteroid sulfotransferase expression in parallel with CYP1A1 induction [373], and 
treatment with β-naphthoflavone or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) caused 
suppression of hydroxysteroid sulfotransferase and aryl sulfotransferase expression in 
primary cultured rat hepatocytes [374]. In a microarray analysis of TCDD treatment 
effects on global gene expression in HepG2 human hepatoma cells, SULT1E1 mRNA 
content was decreased by 60% following treatment with 10 nM TCDD for 8 hr [375]. 
Approximately the same magnitude of suppression occurred when the cells were pre-
treated with cycloheximide prior to TCDD treatment, suggesting that the reduction of 
SULT1E1 mRNA content was a direct effect of TCDD treatment on gene transcription 
and was not secondary to induction of a suppressive factor [375]. Most recently, TCDD 
treatment was reported to cause suppression of SULT1E1 expression in the livers of 
female C57BL/6 mice [376]. 
Taken together, these prior findings prompted us to hypothesize that AhR is the 
molecular switch that confers confluency-dependent expression of SULT1E1 in 
MCF10A cells. We propose that basally active AhR suppresses SULT1E1 transcription 
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in pre-confluent MCF10A cells, while in confluent cells AhR becomes inactive, thereby 
de-repressing SULT1E1 transcription.  
 
Materials and Methods 
 
Materials. TCDD was purchased from Midwest Research Institute (Kansas City, MO). 
3‟-methoxy-4‟-nitroflavone (MNF) was purchased from ICC Chemical Corporation (New 
York, NY). Cell culture medium, L-glutamine, horse serum, penicillin-streptomycin 
solution, sodium pyruvate, Lipofectamine 2000, Superscript II, recombinant human 
SULT1E1, and anti-SULT1E1 antibody were purchased from Invitrogen Corporation 
(Carlsbad, CA). EGF was purchased from BD Biosciences (San Jose, CA). 
Recombinant human insulin (Novolin R) was purchased from Novo Nordisk 
Pharmaceuticals, Inc. (Princeton, NJ). Bromouridine (BrU), cholera toxin, doxycycline, 
hydrocortisone, and puromycin were purchased from Sigma-Aldrich (St. Louis, MO). 
Mouse monoclonal AhR antibody (B-11), goat polyclonal ARNT1 antibody (C-19), rabbit 
polyclonal glyceraldehyde 3-phosphate dehydrogenase antibody (FL-335), and 
horseradish peroxidase-conjugated goat anti-rabbit IgG, goat anti-mouse IgG, and 
donkey anti-goat IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
ECL Plus Western Blotting Detection Reagents and Hybond-P membranes were 
purchased from GE Healthcare (Piscataway, NJ). The microRNA mimic (c-301032-01-
0005 for hsa-miR-100* and c-300578-05-0005 for has-miR-221) was purchased from 
Thermo Fisher Scientific. Other materials were obtained from the sources indicated 
below. 
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Cell culture. The MCF10A cell line was obtained from the Cell Resources Facility of 
the Barbara Ann Karmanos Cancer Institute, Wayne State University and cultured in 
phenol red-free DMEM/F12 Nutrient Mixture (1:1) supplemented with 10 μg/ml insulin, 
20 ng/ml EGF, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone, 5% horse serum, 
100 U/ml penicillin, and 100 μg/ml streptomycin. The cell line was routinely maintained 
in T75 flasks in a 37°C humidified environment of 5% CO2/95% air. For experiments, 
125,000 cells or 1,000,000 cells were plated into 60 mm dishes. At these cell densities, 
approximately 3 days after plating, pre-confluency (~70% confluency) or confluency 
was reached, respectively, and the cells were harvested for preparation of total RNA. 
For TCDD or MNF treatment, 48 hr after plating, cells were treated with 0.1% DMSO 
(control), TCDD or MNF for 24h. 
TaqMan Gene Expression assays. As described in Chapter 2. 
Measuring SULT1E1 heterogeneous nuclear RNA (hnRNA). For measuring the 
amount of SULT1E1 heterogeneous nuclear RNA (hnRNA), total RNA was isolated 
using the RNeasy Mini Kit with on-column DNase I treatment, and samples of total RNA 
(1.5 μg) were reverse transcribed using the High Capacity cDNA Reverse Transcription 
Kit. As negative controls, equivalent amounts of total RNA were “mock reversed 
transcribed” by performing the reactions in the absence of reverse transcriptase. PCR 
primers were designed using Oligo Primer Analysis Software, version 7.36 (Molecular 
Biology Insights, CA) and the human SULT1E1 structural gene sequence (NCBI 
Reference Sequence NC_000004, 70706930-70725870 complement). The sequence 
of the upper primer (5′-GCTGGTCATCCAAATCCTG-3′) was located within exon 5 and 
the sequence of the lower primer (5′-CAATTTGCCTTCTACATCTGGACA-3′) was 
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located within intron 5. Each PCR reaction contained 1 μl of reverse transcription 
reaction as template, 25 μl of 2x SYBR Green PCR Master Mix (Applied Biosystems), 
and 300 nM each of upper and lower primer in a volume of 50 μl. Samples were 
incubated at 95°C for 10 min, followed by 35 cycles of 95°C for 15 sec and 60°C for 1 
min, followed by a melting curve of 95°C for 15 sec, 60°C for 1 min, ramp to 95°C with 
data collection every 0.3°C, and 95°C for 15 sec to ensure that a single product had 
been amplified. A commercial SYBR Green-based RT-PCR assay to detect TATA box 
binding protein was used for normalization (Qiagen, Valencia, CA). Following data 
acquisition, Ct values were determined and data were analyzed as described above. 
Control reactions containing aliquots of the mock reverse transcribed samples were 
performed to determine whether any fluorescent signal was derived from contaminating 
genomic DNA. To confirm amplification of the specific target fragment of expected size 
(203 nt),
 
PCR products were run on a 2% agarose gel and visualized with ethidium 
bromide under ultraviolet illumination. 
microRNA microarray analysis. Total RNA was prepared from different confluency 
MCF10A cells using Trizol reagent (Gibco). The quality of each sample used was 
checked using the RNA Nano Kit and an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA). The following microRNA microarray procedures were 
performed by the Microarray/Bioinformatics Core Facility. MicroRNA microarray 
analysis was performed using the microRNA Microarray System (Agilent Technologies, 
Palo Alto, CA). Each Human microRNA Microarray V2 (Cat. No. G4470B) slide contains 
8 microRNA arrays. Each array consists of human and human viral microRNAs from the 
Sanger miRBASE 10.1. Agilent protocol “microRNA Microarray System” v. 1.5 was 
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followed during microRNA labeling and array hybridization. Samples of total RNA (100 
ng) were treated with Calf Intestine Alkaline Phosphatase (GE Healthcare Bio-Sciences 
Corp., Piscataway, NJ) at 37° C for 30 min. Ligation reactions were performed at 16° C 
for 2 hr. The labeled microRNA samples were then purified using Micro Bio-Spin 6 
columns (Bio-Rad Laboratories, Hercules, CA), dried with a speed vac, and re-
suspended in 18 µl of nuclease-free water. 4.5 µl of 10× GE Blocking Agent and 22.5 µl 
of Agilent 2× Hi-RPM Hybridization Buffer were added, and the samples were incubated 
at 100° C for 5 min and placed on ice for 5 min. Samples were immediately added to an 
array in an Agilent SureHyb hybridization chamber. The hybridization chambers were 
rotated at 20 rpm in a hybridization oven for 20 hr at 55° C. After hybridization, the 
slides were removed from the hybridization chamber and placed in a glass slide rack in 
a slide-staining dish for washing. The staining dish was placed on a magnetic stir plate, 
and stirred using setting 4. The slides were washed 5 min in GE Wash Buffer 1 and 5 
min in pre-warmed 37° C GE Wash Buffer 2 (Agilent Technologies). Slides were slowly 
removed from wash 2 solution which allows for even drying across the slide. Slides 
were then scanned using the Agilent dual laser scanner. The photomultiplier tube 
settings were set at 100% and 5% for the Green channel. Tiff images were analyzed 
using Agilent‟s feature extraction software. 
microRNA over-expression. MCF10A cells were seeded into 24-well plates (150,000 
cells/well). The following day, the standard medium was replaced with Opti-MEM 
containing a premixed complex of 4 µl of the microRNA mimic (c-301032-01-0005 for 
hsa-miR-100* and c-300578-05-0005 for has-miR-221). The next day, cultures (3 wells 
per treatment group) were harvested for RNA. RNA samples (1.5 µg) were reverse 
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transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA). The levels of miroRNA were measured using the 
following TaqMan MiroRNA assays: has-miR-100* and has-miR-221. 
BrU pulse-chase labeling. The BrU procedure was performed by collaborator Dr. Mats 
Ljungman at the University of Michigan. MCF10A cells grown to pre-confluency or 
confluency were incubated with 2 mM BrU in conditioned medium for 30 min to label 
nascent RNA. Cells were then washed 3 times in PBS and either collected directly (0 hr 
time point) or chased in conditioned medium containing 20 mM uridine for 2 or 6 hr at 
37°C. Total RNA was isolated using TRIzol reagent and the BrU-containing RNA was 
isolated using magnetic beads (Dynabeads, Goat anti-mouse IgG, Invitrogen) 
conjugated to anti-BrdU monoclonal antibody (BD Biosciences). Conversion of the 
isolated BrU-containing mRNA into cDNA and real-time PCR analyses were performed 
by the Microarray Core of the University of Michigan Comprehensive Cancer Center 
according to protocols supplied by the manufacturer (SABiosciences, Frederick, MD). 
For the real-time PCR analyses, the Cancer Drug Resistance and Metabolism real-time 
RT PCR array (PAHS-004, SABiosciences) and the ABI 7900HT Sequence Detection 
System from Applied Biosystems were used. The data were analyzed using RT
2
 Profiler 
PCR Array Data Analysis software 
(http://www.sabiosciences.com/pcr/arrayanalysis.php), and the data were normalized to 
the expression of 5 housekeeping genes present on the arrays. The housekeeping 
genes were: β2-microglobulin, hypoxanthine phosphoribosyltransferase 1 (HPRT1), 
ribosomal protein L13A, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-
actin. 
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Western blot analysis. For measurement of SULT1E1 protein content, MCF10A cells 
in T75 flasks were washed with PBS and scraped into ice-cold PBS. Cells were pelleted 
and homogenized by sonication in buffer (200 µl per flask) consisting of 50 mM Tris-HCl, 
25 mM sucrose, 1 mM EDTA and 1x Halt protease inhibitor (Thermo Fisher Scientific, 
Rockford, IL), pH 7.4. Homogenates were centrifuged at 20,000xg, 4°C for 20 min, and 
supernatants were used for western blot analysis. Protein concentrations were 
measured using the BCA Protein Assay (Thermo Fisher Scientific). Western blot 
analysis was performed as described previously [250], using 60 µg of sample protein, 
SULT1E1 antibody at a dilution of 1:2000, secondary antibody at a dilution of 1:10,000, 
and enhanced chemiluminescence for immunoreactive protein detection. For western 
blot analysis of AhR and ARNT, MCF10A cells in 10 cm dishes were washed twice with 
PBS and then lysed using 700 μl of cold RIPA buffer (Thermo Fisher Scientific). For 
SDS-PAGE, 30 µg samples of the lysates were separated on 4-20% Precise Protein 
Gels (Thermo Fisher Scientific). Following transfer to polyvinylidene difluoride 
membranes, the blots were developed using AhR antibody (1:500) or ARNT antibody 
(1:400) and secondary antibodies at 1:10,000 dilutions. Western blots were normalized 
for variations in protein loading and transfer by reincubation with a GAPDH antibody 
(1:1000). 
MCF10A cells stably expressing an AhR-responsive reporter. MCF10A cells were 
plated into 6-well plates (700,000 cells/well). The following day, 4 µg pGudLuc 
(provided by Dr. Michael Denison, University of California, Davis, CA), which contains 4 
dioxin response element (DREs), and 0.65 µg pSV2neo (American Type Culture 
Collection, Manassas, VA) were cotransfected into MCF10A cells using Lipofectamine 
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2000. After 24 hr recovery in standard medium, transfected cells were re-plated into 
medium containing 550 µg/ml G418. After two rounds of limiting dilution cloning, 
individual cell clones were identified and expanded. For TCDD treatment, 50,000 or 
500,000 cells were plated into 6-well plates and 48 hr after plating, cells were treated 
with 0.1% DMSO or TCDD for 24 hr. After treatment, growth medium was removed and 
cells were washed with PBS. Passive Lysis Buffer (Promega Corporation, Madison, WI) 
was added to each well (500 µl/well) and protein concentrations were measured in 
lysates using the BCA Protein Assay (Thermo Fisher). Firefly luciferase activities were 
measured in aliquots containing 10 µg protein using the Dual Luciferase Reporter 
Assay System (Promega Corporation, Madison, WI) and an LMAX II384 microplate 
reader (Molecular Devices Corporation, Sunnyvale, CA) equipped with SoftMaxPro 
software. 
Conditional knockdown of AhR in MCF10A cells. A plasmid expressing a microRNA-
adapted shRNA targeting human AhR in a doxycycline-inducible manner (oligo ID 
V2THS_132482, vector pTRIPZ) was purchased from Thermo Fisher Scientific, Open 
Biosystems Products (Huntsville, AL). For transfection, 700,000 MCF10A cells were 
plated into 6-well plates, and 4 µg/well plasmid was transfected into the cells using 
Lipofectamine 2000 24 hr after plating. Stably-transfected cells were obtained by 
incubation in culture medium containing 1 μg/ml puromycin followed by limiting dilution 
cloning. To achieve AhR knockdown, cells were treated with 1 µg/ml doxycycline for 96 
hr. 
Transfection of a SULT1E1 5’-flanking region-luciferase reporter plasmid. A 
fragment of the human SULT1E1 gene spanning from nt -7073 to +13 was amplified by 
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PCR using genomic DNA from the MCF10A cells line as template, forward primer: 5′-
GGGGGTACCATTTGGCCTGCTATAACTGTATGCT-3′ (underscored sequence is a 
KpnI site), and reverse primer: 5‟-GGGCTCGAGACTTCTGCATTTGGAATGTTTCTGG-
3‟ (underscored sequence is a XhoI site). The amplified fragment was ligated into the 
KpnI and XhoI sites of the pGL4.17[luc2/Neo] reporter plasmid (Promega Corporation, 
Madison, WI). The sequence of the SULT1E1 fragment was verified using the services 
of the Applied Genomics Technology Center, Wayne State University. 
For stable transfection, 700,000 MCF10A cells were plated into 6 well plates. 
The following day, the cells were transfected with 4 µg of the SULT1E1 5‟-flanking 
region-luciferase reporter plasmid using Lipofectamine 2000. After 24 hr recovery in 
standard medium, the transfected cells were re-plated into medium containing 550 
µg/ml G418 and expanded. 
For transient transfections, MCF10A cells or MCF10A cells engineered for 
conditional knockdown of AhR and treated with either 0.1% DMSO or 1 µg/ml 
doxycycline for 96 hr were seeded into 24-well plates (150,000 cells/well). The following 
day, the standard medium was replaced with Opti-MEM containing a premixed complex 
of 4 µl of Lipofectamine 2000, 0.8 µg SULT1E1-luciferase reporter, and 1.25 ng pRL-
SV40 (Promega). The next day, cultures (3 wells per treatment group) were incubated 
with fresh medium containing 0.1% DMSO, 1-3 µM MNF, or 1 µg/ml doxycycline for 24 
hr. The cells were then harvested for measurement of firefly and Renilla luciferase 
activities using the Dual Luciferase Reporter Assay System (Promega Corporation, 
Madison, WI) and an LMAX II384 microplate reader (Molecular Devices Corporation, 
Sunnyvale, CA) equipped with SoftMaxPro software.  
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Computational analysis of SULT1E1 5’-flanking region for DREs and site-directed 
mutagenesis. The region of the human SULT1E1 gene spanning from 10 kb upstream 
of the transcription start site (as indicated by the beginning of exon 1) through exon 1 
was retrieved from NCBI (nt 70,725,767 through 70,735,870 of NC_000004) and was 
evaluated for the presence of DREs using MatInspector (Genomatix Software, Ann 
Arbor, MI) [377]. The V$AHRR (AHR-arnt heterodimers and AhR-related factors) matrix 
family was used for the search, and sites were considered to be matches if the 
calculated matrix similarity was greater than the optimized matrix threshold. 
A single nt change (C to A) was introduced into the core region of a DRE 
predicted to be located at nt -3476 of the SULT1E1 gene within the context of the 
luciferase reporter plasmid containing 7073 of the SULT1E1 5‟-flanking sequence. This 
nt change has been shown to abolish the ability of the AhR•ARNT heterodimer to bind 
to a DRE [378]. The nt change was introduced using the QuickChange II XL Site-
Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA), forward primer: 5′-
ACAGCAAAAACCTGGGAGTGCATGTGCACACAC-3′, and reverse primer: 5′-
GTGTGTGCACATGCACTCCCAGGTTTTTGCTGT-3′. The presence of the mutation 
was confirmed by sequence analysis. 
Statistical analysis.  As described in Chapter 2 
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Fig. 3.1 SULT1E1 expression in pre-confluent and 
confluent MCF10A cells. MCF10A cells were harvested at 
approximately 70% and 100% confluency. A: SULT1E1 
mRNA levels were measured in 6 independent 
experiments using a TaqMan Gene Expression Assay. B: 
SULT1E1 immunoreactive protein levels were measured in 
2 independent experiments by western blot hybridization. 
C: SULT1E1 hnRNA levels were measured in 6 
independent experiments using a SYBR green real-time 
RT-PCR assay. In panels A and C, data are expressed as 
mean ± SEM, and ***p<0.001 compared to pre-confluent 
cells.  
 
 
Results 
As shown in Chapter 
2, SULT1E1 mRNA is 
expressed at a higher 
level in confluent 
MCF10A cells than in 
pre-confluent cells 
[250]. To characterize 
the phenomenon 
more fully, we first 
confirmed the initial 
finding and then 
demonstrated that 
confluency-mediated 
up-regulation of 
SULT1E1 expression 
occurred at the 
protein level (Fig. 
3.1A and 3.1B). We 
next addressed 
whether the 
confluency-mediated 
increase in SULT1E1 mRNA content was the result of increased 
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mRNA synthesis or decreased mRNA degradation. The relative levels of SULT1E1 
hnRNA were measured in pre-confluent and confluent MCF10A cells as an 
approximation of transcription rate. SULT1E1 hnRNA levels were significantly higher 
(~8.7-fold) in confluent than in pre-confluent MCF10A cells (Fig. 3.1C). By measuring 
SULT1E1 mRNA content at different times after re-plating confluent MCF10A cells, the 
half-life of SULT1E1 mRNA in pre-confluent cells was estimated to be 3.4 hr (Fig. 3.2A). 
 
Fig. 3.2 Relative rates of SULT1E1 mRNA synthesis and degradation in pre-
confluent and confluent MCF10A cells. A: Confluent MCF10A cells were 
subcultured and harvested at the indicated times post-plating for measurement of 
SULT1E1 mRNA levels. SULT1E1 mRNA content is expressed as the log of the 
fractional level measured in confluent MCF10A cells, and the first order half-life was 
calculated from the least squares line. B: Bromouridine labeling was used to 
measure relative rates of SULT1E1 mRNA synthesis and degradation in pre-
confluent and confluent MCF10A cells. The data represent the averages from two 
independent experiments. 
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Fig. 3.3 Confluency-related decrease in miR-221 and miR-
100*.  MCF10A cells were harvested at approximately 70% and 
100% confluency. The miR-221 and miR-100* mRNA levels were 
measured in 3 independent experiments using TaqMan MicroRNA 
Assays. Data are expressed as mean ± sd, and *p<0.05 
compared to pre-confluent cells. 
 
Since microRNAs have emerged as important regulators of translation and 
mRNA decay, we analyzed the expression of microRNAs in MCF10A cells at different 
confluencies. Microarray analysis done by the Microarray/Bioinformatics core facility (Dr. 
Alan Dombkowski, Department of Pediatrics, Children's Hospital of Michigan)   
revealed that 85 
microRNAs were 
significantly up-
regulated and 24 
microRNAs were 
down-regulated 
in confluent 
relative to pre-
confluent 
MCF10A cells. 
Computational 
analysis of the 
SULT1E1 3‟-untranslated region identified 4 candidate binding sites for confluency-
regulated microRNAs. The confluency-related decrease in two of these microRNAs 
(miR-221 and miR-100*) corresponded with the confluency-induced increase in 
SULT1E1 mRNA observed in MCF10A cells (Fig. 3.3). However, overexpression of 
miR-100* or miR-221 did not suppress SULT1E1 expression in confluent MCF10A cells, 
suggesting that the down-regulation of these microRNAs is not responsible for 
confluency-induced SULT1E1 expression (Fig. 3.4). 
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Fig. 3.4 Overexpression of miR-100* or miR-221 did not 
suppress SULT1E1 expression in confluent MCF10A cells. 
Confluent MCF10A cells were transiently transfected with miR-
100* (A, B) or miR-221 (C, D). Forty-eight hours after transfection, 
the cells were harvested for the measurement of microRNA (A, C) 
and SULT1E1 mRNA (B, D) levels. 
Our collaborator, Dr. Mats Ljungman of the Radiation Oncology Department, 
University of Michigan, recently developed an innovative approach to measure the 
relative rates of 
mRNA synthesis 
and degradation 
(Ljungman et al., 
submitted). We 
submitted 
material for this 
analysis and 
found that the 
rate of SULT1E1 
mRNA synthesis 
was was 55.6-
fold higher in 
confluent than in 
pre-confluent cells, while the rate of SULT1E1 mRNA degradation was 7.3-fold higher 
in confluent than in pre-confluent cells (Fig. 3.2B). Taken together, these results 
indicate that increased SULT1E1 mRNA stability cannot account for the increased 
SULT1E1 mRNA content that is seen upon cell confluence, and that confluence-
mediated up-regulation is most likely due to increased transcription.  
As described in the Introduction, confluence-mediated SULT1E1 up-regulation is 
mirrored by down-regulation of two CYPs, CYP1A1 and CYP1S1, that are known 
67 
 
 
 
 
Fig. 3.5 Indices of AhR activity in pre-confluent and confluent 
MCF10A cells. A: MCF10A cells were harvested at approximately 
70% and 100% confluency, and CYP1A1 mRNA levels were 
measured using a TaqMan Gene Expression Assay. Data are 
expressed as mean ± SEM of 3 independent experiments. B: 
MCF10A cells stably expressing an AhR-responsive luciferase 
reporter were treated for 24 hr with 0.1% DMSO or 30 nM TCDD 
prior to harvest at approximately 70% and 100% confluency for 
luciferase determinations. Data are expressed as mean ± sd, 3 
wells per treatment group. *** p<0.001 compared to pre-confluent 
cells. 
 
transcriptional targets of AhR [365], suggesting that AhR might provide the mechanistic 
link between these phenomena. Using real-time RT-PCR, we confirmed that CYP1A1 
mRNA content 
was significantly 
higher in pre-
confluent 
MCF10A cells 
than in confluent 
cells (Fig. 3.5A). 
To evaluate 
further whether 
AhR activity 
varies as a 
function of 
MCF10A 
confluency, the 
cells were 
engineered to 
express firefly luciferase under the control of 4 DREs. TCDD treatment significantly 
increased luciferase reporter expression, demonstrating responsiveness of the 
engineered cells to AhR activation (Fig. 3.5B). Luciferase expression was significantly 
(~4.5-fold) higher in pre-confluent cells than in confluent cells, supporting the 
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Fig. 3.6 Expression of AhR and ARNT in pre-confluent and confluent MCF10A 
cells. A: MCF10A cells were harvested at approximately 70% and 100% confluency. 
A: AhR and ARNT mRNA levels were measured in 6 independent experiments using 
TaqMan Gene Expression Assays. Data are expressed as mean ± SEM, and 
***p<0.001 compared to pre-confluent cells. B: AhR and ARNT immunoreactive 
protein levels were measured in 2 independent experiments by western blot 
hybridization. C: BrU labeling was used to measure relative rates of AhR mRNA 
synthesis and degradation in pre-confluent and confluent MCF10A cells. The data 
represent the averages from two independent experiments. 
conclusion that AhR is basally active in pre-confluent MCF10A cells but less active in 
confluent cells (Fig. 3.5B).  
The mRNA levels of AhR and its heterodimerization partner ARNT were ~3.0- 
and ~1.8-fold higher, respectively, in pre-confluent than in confluent cells, and the 
immunoreactive protein levels were correspondingly higher in pre-confluent cells (Fig. 
3.6A and 3.6B). The higher levels of AhR mRNA and protein in pre-confluent than 
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Fig. 3.7 Effects of AhR agonist and antagonist treatments on CYP1A1 and 
SULT1E1 expression in MCF10A cells. A and B: Pre-confluent cultures of 
MCF10A cells were treated for 24 hr with 0.1% DMSO, 30 nM TCDD, 1 µM MNF, or 
TCDD and MNF in combination and harvested for measurement of CYP1A1 (A) 
and SULT1E1 (B) mRNA levels. Data are expressed as mean ± SEM of triplicate 
assays. C and D: Pre-confluent and confluent cultures of MCF10A cells were 
treated for 24 hr with DMSO, MNF, or TCDD and harvested for measurement of 
CYP1A1 (C) and SULT1E1 (D) mRNA levels. Data are expressed as mean ± SEM 
of 3 independent cell culture experiments. *** P<0.001 compared to pre-confluent 
cells, * P<0.05 
 
confluent cells are likely attributable to differences in mRNA stability since, using the 
aforementioned bromouridine labeling technique, the rates of AhR mRNA synthesis and 
degradation were determined to be 5.5- and 11.3-fold higher, respectively, in confluent  
MCF10A cells than in pre-confluent cells (Fig. 3.6C). 
To investigate the role of AhR in regulating SULT1E1 expression, we tested the 
effects of TCDD, a potent AhR agonist, and MNF, an AhR antagonist, on CYP1A1 and 
SULT1E1 expression in MCF10A cells. In pre-confluent cells, 30 nM TCDD treatment 
increased CYP1A1 mRNA content by 547-fold, while treatment with 1 µM MNF, a 
concentration sufficient to abolish TCDD-mediated induction, decreased basal CYP1A1 
mRNA content by >99% (Fig. 3.7A). By comparison, TCDD treatment of pre-confluent 
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Fig. 3.8 Effect of AhR knockdown on CYP1A1 and SULT1E1 expression in pre-
confluent MCF10A cells. A and B: Pre-confluent MCF10A cells engineered for 
conditional knockdown of AhR were treated for 96 hr with 0.1% DMSO or 1 µg/ml 
doxycycline and harvested for measurement of AhR mRNA (A) and immunoreactive 
protein (B) levels. In panel A, data are expressed relative to DMSO-treated cells as 
mean ± SEM of 3 independent cell culture experiments. ***p<0.001 compared to 
DMSO treated cells. C: Pre-confluent cells were treated for 96 hr with DMSO or 
doxycycline, either alone or in combination with 1 µM MNF or 30 nM TCDD, and 
harvested for measurement of CYP1A1 and SULT1E1 mRNA levels. Data are 
expressed as mean ± SEM of three independent cell culture experiments. 
***P<0.001, ** P<0.01, * P<0.05 compared to DMSO-treated cells. 
 
MCF10A cells decreased SULT1E1 mRNA content by ~57%, while MNF treatment 
increased the amount of SULT1E1 mRNA by ~6.7-fold (Fig. 3.7B). 
Comparing the effects of TCDD and MNF treatments in pre-confluent MCF10A 
cells with those in confluent cells, TCDD-mediated CYP1A1 mRNA induction in 
confluent cells was not attenuated relative to the induction seen in pre-confluent cells, 
despite the lower levels of AhR and ARNT, demonstrating the high efficacy of this AhR 
agonist. As shown before, basal levels of CYP1A1 mRNA were significantly higher in 
pre-confluent cells than in confluent cells. MNF treatment abolished basal CYP1A1 
expression in both pre-confluent and confluent cells (Fig. 3.7C). 
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Fig. 3.9 Effects of MNF treatment, cell confluency, or AhR knockdown on 
luciferase expression from a reporter plasmid containing 7073 of the 
SULT1E1 5’-flanking sequence. A. MCF10A cells were stably transfected with the 
SULT1E1-luciferase reporter plasmid and pre-confluent cells were treated with 1 to 
10 µM MNF for 24 hr, after which they were harvested for measurement of firefly 
luciferase activity and protein content. Each bar represents the mean ± sd of 
normalized luciferase activity (3 wells per treatment group). Groups that do not 
share a capital letter are significantly different from each other (p<0.001). B. Pre-
confluent and confluent MCF10A cells stably transfected with the SULT1E1-
luciferase reporter were harvested for measurement of luciferase activity as 
described above (A). ***p<0.001 compared to pre-confluent cells. C. Pre-confluent 
MCF10A cells were transiently transfected with the SULT1E1-luciferase reporter 
containing either an intact (white bars) or mutated (black bars) predicted DRE at -
3476, treated for 24 hr with 1 to 10 µM MNF, and harvested for measurement of 
luciferase activities. Each bar represents the man ± sd of normalized (firefly/Renilla) 
luciferase activities (3 wells per treatment group). Groups that do not share a capital 
letter are significantly different from each other (p<0.05). D. Pre-confluent MCF10A 
cells engineered for conditional knockdown of AhR were treated with either 0.1% 
DMSO or 1 µg/ml doxycycline for 96 hr and transiently transfected with SULT1E1-
luciferase reporter containing intact or mutant DRE. Twenty-four hr after 
transfection, cells were harvested for measurement of firefly and Renilla luciferase 
activities. Groups that do not share a capital letter are significantly different from 
each other (p<0.001). 
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For SULT1E1, mRNA levels were significantly higher in confluent cells, and TCDD 
treatment suppressed expression in both pre-confluent and confluent cells. MNF 
treatment increased SULT1E1 expression in pre-confluent cells but not in confluent 
cells (Fig. 3.7D), suggesting that confluency and MNF treatment increase SULT1E1 
expression through a common mechanism.  
As a complementary approach, MCF10A cells were engineered for conditional 
(doxycycline-mediated) knockdown of AhR expression. A significant reduction of AhR 
mRNA content (by ~68%), accompanied by a marked decrease in AhR immunoreactive 
protein level, was achieved when the engineered cells were treated with doxycycline for 
96 hr (Fig. 3.8A and 3.8B). Doxycycline treatment also caused a significant reduction in 
TCDD-inducible CYP1A1 mRNA expression (Fig. 3.8C), although the reduction was 
only ~30%, again indicating that this potent and efficacious AhR agonist can produce a 
substantial signal even in the presence of reduced AhR levels. 
When pre-confluent cells were treated for 96 hr with doxycycline, CYP1A1 
mRNA levels were significantly reduced (by ~78%) while SULT1E1 mRNA levels were 
significantly increased (by ~2.5-fold) (Fig. 3.8C and 3.8D). The doxycycline-mediated 
increase in SULT1E1 mRNA content was comparable to the increase that was 
produced when cells with intact AhR expression (i.e., not treated with doxycycline) were 
treated with MNF. Also, co-treatment with doxycycline and MNF did not produce an 
additive effect, indicating that the effects of doxycycline and MNF on SULT1E1 
expression were mediated through the common mechanism of AhR disruption.  
Computational analysis of 10Kb of the SULT1E1 5‟-flanking region identified two 
candidate DREs, one at 8138 and one at 3476 nt upstream of the transcription start site. 
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A fragment containing 7073 nt of the SULT1E1 5‟-flanking region was ligated into a 
luciferase reporter plasmid, and this plasmid was used for stable or transient 
transfection of MCF10A cells. Treatment of stably transfected, pre-confluent MCF10A 
cells with MNF caused a concentration-dependent increase in reporter gene expression 
(Fig. 3.9A). Also, luciferase expression was significantly higher in confluent than in pre-
confluent stably transfected MCF10A cells (Fig. 3.9B), indicating that the information 
responsible for both confluence- and MNF-inducible SULT1E1 transcription is 
contained within the 7 kb 5‟-flanking region. MNF treatment also increased luciferase 
expression in pre-confluent MCF10A cells that had been transiently transfected with the 
7 kb SULT1E1 reporter plasmid (Fig. 3.9C). Transfection of a SULT1E1 plasmid 
containing a site-directed mutation in a core nucleotide of the DRE at -3476 did not 
attenuate MNF-mediated reporter induction (Fig. 3.9C). Also, transient transfection of 
the 7 kb SULT1E1 reporter plasmid into the MCF10A cells that had been engineered 
for conditional AhR knockdown resulted in doxycycline-inducible reporter expression, 
and mutation of the DRE did not affect this up-regulation (Fig. 3.9D). These findings 
indicate that AhR inhibition/suppression-mediated SULT1E1 up-regulation is not 
mediated through the DRE at -3476. 
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Discussion 
 
The impact of manipulations that alter cell-cell or cell-matrix contacts on AhR 
target gene expression was first investigated by Sadek and Allen-Hoffmann [379], who 
reported that the suspension of cultured human keratinocytes caused increased 
expression of CYP1A1 and other AhR target genes. Further studies using Hepa1c1c7 
murine hepatoma cells and variants defective in AhR signaling confirmed that cell 
suspension caused activation of the AhR [380]. Subsequently, Monk et al. [381] 
reported that suspension of cultured rat keratinocytes caused transient AhR activation 
and CYP1A1 induction, and that co-treatment with the AhR antagonist, α-
naphthoflavone, inhibited suspension-mediated CYP1A1 induction. 
Cho et al. [382] then demonstrated that either suspension or monolayer culture 
at low confluency caused activation of the AhR in C3H10T1/2 fibroblast clonal sub-lines. 
An important conclusion from these studies was that disruption of cell-cell contact, 
rather than removal from the substratum, was responsible for AhR activation. Relative 
to confluent C3H10T1/2 cells, in ~70% confluent cells, there was ~4-fold activation of 
an AhR-responsive reporter, which is approximately the same magnitude of CYP1A1 
mRNA and pGudLuc up-regulation that we observed in confluent versus pre-confluent 
MCF10A cells. In very low (5%) confluence C3H10T1/2 cells, AhR-responsive reporter 
expression was activated ~13-fold, which was approximately the same magnitude that 
occurred after TCDD treatment [382]. Treatments with several inhibitors of processes 
involved in AhR•ARNT complex formation inhibited AhR activation whether it was 
produced by TCDD treatment or loss of cell-cell contact, indicating that these stimuli 
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induced AhR•ARNT complex formation through the same mechanism. However, some 
treatments that interfere with the transcriptional activity of AhR•ARNT complexes 
produced stimulus-dependent effects on AhR activation, suggesting that the AhR•ARNT 
complexes are regulated differently after TCDD treatment and loss of cell-cell contact. 
A notable difference from the findings of Monk et al. [381] was that α-naphthoflavone 
treatment blocked TCDD-mediated AhR activation but not activation by loss of cell-cell 
contact. Consistent with the findings of Monk et al., we found that AhR inhibitor 
treatment (MNF) reduced the level of CYP1A1 expression in pre-confluent MCF10A 
cells. 
Most recently, Ikuta et al. [383] reported that cell density influenced the 
subcellular distribution of AhR and AhR activity. AhR was predominantly nuclear in the 
HaCaT human keratinocyte cell line at low confluence, both nuclear and cytoplasmic at 
pre-confluence, and predominantly cytoplasmic at confluence. They also used a cell-
scrape model of in vitro wound healing to demonstrate that AhR became activated in 
the loosely-associated cells at the border of the wound margin [383]. These 
investigators hypothesized that loss of cell-cell contact activates signaling events, 
possibly mediated through p38 MAPK, that increase the phosphorylation of AhR at its 
nuclear export signal, which causes AhR to accumulate in the nucleus [383]. 
AhR function has also been linked to the cell cycle. For example, Santini et al. 
[384] used centrifugal elutriation to isolate populations of TCDD-treated human 
monocytic U937 cells in different phases of the cell cycle, and reported that late 
G1/early S phase cells had CYP1A1 mRNA contents that were ~1.4- and 3-fold higher 
than the contents of asynchronous/early G1 and G2/M cultures, respectively. These 
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studies suggest that the transcriptional activation of AhR target genes by TCDD is cell 
cycle-dependent and suppressed in G2/M cells. However, Cho et al. reported that 
absence of cell-cell contact in low-density culture induced AhR activation was cell cycle 
independent because three G1/S phase inhibitors treatment did not affect this cell-
confluency-mediated AhR up-regulation [382]. Similarly, Ikuta et al. confirmed this 
finding by showing that BrdUrd labeled S-phase cells had the same nuclear localization 
of AhR as cells in other cell cycle phases [383]. 
One possible mechanism for AhR-mediated transcriptional suppression is 
through the binding of the activated AhR•ARNT complex to an inhibitory DRE. Safe and 
co-workers have reported that certain genes (i.e., cathepsin D, c-fos, pS2, and Hsp27) 
contain pentanucleotide GCGTG sites that correspond to the core DRE motif and 
function as inhibitory DREs in that the binding of liganded AhR to these sites inhibits 
estrogen-mediated transcriptional activation by disrupting the binding of ER or other 
transcription factors to activating sites that are located in proximity to the DREs (for 
review, see [385]). Computational analysis of 10 kb of the SULT1E1 5‟-flanking region 
identified two high-scoring AhR•ARNT binding sites: one at 8138 and one at 3476 nt 
upstream of the transcription start site. Of note, both of these DRE sites were identified 
as matches to the V$AHRARNT.03 matrix, which was compiled using, among other 
sequences, the inhibitory DRE sites contained in the cathepsin D and Hsp27 genes. 
Although a reporter construct containing ~7 kb of SULT1E1 5‟-flanking sequence, and 
therefore the DRE at –3476, showed significant up-regulation in response to MNF 
treatment, AhR knockdown, or cell confluency, site-directed mutagenesis of the DRE 
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did not affect the up-regulation, suggesting that this DRE does not play a role in the 
negative regulation of SULT1E1 transcription. 
It is therefore probable that AhR suppresses SULT1E1 transcription by 
modulating the activity of some other transcription factor. AhR has been shown to 
interact physically with a variety of transcription factors or transcription factor 
modulatory proteins, including nuclear receptors ERα, COUP-TFI, and ERRα1 [386]; 
NFκB subunits RelA and RelB [387;388]; the cell cycle regulatory protein Rb [389]; and 
the apoptosis regulatory transcription factor E2F1 [390], thereby modulating their 
activities either positively or negatively. AhR also engages in cross-talk interactions with 
MAP kinases [390], which might modify the activities of MAP kinase-regulated 
transcription factors in MCF10A cells. 
Our results add to the growing number of mechanisms by which AhR modulates 
estrogenic activity. Anti-estrogenic effects of AhR ligands, in particular, have been 
extensively studied, and several mechanisms underlying such effects have been 
reported (for review, see [385]), including (1) AhR-mediated induction of one or more 
enzymes (e.g., CYP1B1) that metabolize estrogen and thereby reduce tissue active 
estrogen concentrations [391]; (2) AhR-mediated induction of a transcription inhibitory 
factor [392]; (3) an inhibitory action mediated by the non-productive binding of liganded 
AhR to an ER target gene, which prevents ER from binding [393]; (4) association of 
liganded AhR with ER, thereby disrupting a transcriptionally productive interaction 
between ER and Sp1 [394]; (5) AhR -mediated reduction of cellular ER levels, by either 
suppression of ER transcription [395] or acceleration of ER degradation through AhR -
mediated recruitment of both ER and proteosome machinery [396]; and (6) AhR-
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mediated transcriptional activation of its target genes, resulting in competition for 
recruitment of the limited pool of co-activators that are shared by the Ah receptor and 
ER. In this regard, ARNT is said to function as a co-activator for ER, but with selectivity 
for ERβ. Thus, ARNT recruitment to AhR-target genes can reduce the transcription of 
ER-target genes [397]. Concerning pro-estrogenic effects, Ohtake et al. [398] reported 
that AhR ligand treatment can induce ER-mediated transcription through the formation 
of an AhR•ARNT•ER complex. By this mechanism, the ligand-bound AhR•ARNT 
heterodimer “hijacks” ER to enable the transcription of ER target genes in the absence 
of an ER ligand [399]. In other studies, AhR ligands have been found to activate ER-
mediated transcriptional activity without a requirement for the AhR [400;401]. 
Abdelrahim et al. [401] reported that AhR ligands 3MC and PCB126 were both capable 
of activating ER in MCF7 breast cancer cells, while Shipley and Waxman [400] found 
that 3MC, but not PCB126 or TCDD, functioned as an ER agonist in Ishikawa uterine 
cancer cells. In another study, Boverhof et al. [402] reported that TCDD treatment of 
OVX mice altered the expression of numerous uterine genes that were comparably 
regulated by 17α-ethynylestradiol. Co-treatment of mice with the pure anti-estrogen ICI 
182,780 (ICI) inhibited both the 17α-ethynylestradiol- and the TCDD-mediated effects 
on these genes [402]. In another study in mice, AhR was shown to be required for the 
expression of CYP19 in the ovary, and treatment with the AhR ligand 9,10-dimethyl-1,2-
benzanthracene increased ovarian expression of CYP19 [403]. By demonstrating that 
AhR activation suppresses expression of SULT1E1, a major estrogen-inactivating 
enzyme, our study provides another mechanism by which AhR can regulate 
estrogenicity. 
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We suggest that AhR-mediated regulation of SULT1E1 plays an important role in 
modulating estrogen mitogenicity in normal breast tissue. When the breast cells are in a 
non-proliferative state, it is essential that the growth stimulatory effects of estrogen be 
held to an absolute minimum. Therefore, cell-cell contact triggers molecular events that 
include inhibition of AhR activity and up-regulation of SULT1E1 activity. When the 
breast cells switch to a proliferative state, a lessening of cell-cell contact causes 
activation of AhR activity and suppression of SULT1E1 expression, resulting in 
increased active estrogen levels in the breast microenvironment. 
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CHAPTER 4 
 
TSC down-regulates SULT1E1 expression in MCF10A human breast epithelial 
cells through an AhR-mediated mechanism 
 
Introduction 
 
Smoking, one of the leading environmental etiologic factors that is associated 
with human cancers in different organs, causes diseases not only in the directly 
exposed tissues of the respiratory tract but also in distant organs such as bladder and 
pancreas [222;404-407]. Heart disease, which is the primary cause of death in 
developed countries, and about 90% of lung cancer, which is a leading cause of 
cancer-related death resulting in 1.2 million deaths annually, have been closely 
associated with tobacco smoking [408-410]. In addition, some evidence supports an 
association between tobacco smoking and breast cancer. For example: 
Tobacco smoke contains carcinogens, including polycyclic aromatic 
hydrocarbons (PAHs), aromatic amines,
 
and N -nitrosamines, which have been shown 
to play important roles at different stages of breast cancer development [404;409;411-
413]. These lipophilic carcinogens are able to pass through the alveolar membrane and 
be transported to the breast through the circulatory system [414;415]. Moreover, these 
fat soluble compounds can be stored in breast adipose tissue and undergo further 
metabolism in situ by breast epithelial cells, which has been supported by the finding 
that the breast fluid of non-lactating tobacco smokers contains mutagenic tobacco 
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compounds and their metabolites, such as nicotine and its major metabolite, cotinine 
[416;417]. These carcinogens and their electrophilic intermediates, such as 
benzo[a]pyrene (BP), crotonaldehyde (2-butenal), and acetaldehyde, covalently bind to 
nucleic acid and form carcinogen-DNA adducts, which may lead to mutation of 
oncogenes and tumor suppressor genes and malignant cell transformation [418-422]. 
Accumulated in vitro exposure to BP, a PAH found in tobacco smoke, transforms 
normal human breast epithelial cells to a precancerous stage [423].            
Tobacco smoke may produce genotoxic effects in breast tissue because it 
increases the prevalence and spectrum of p53 mutations and alters the expression of 
genes involved in DNA repair and carcinogen metabolism, including CYP family 
members, catechol-O-methyltransferase, glutathione-S-transferases and N-
acetyltransferase  [424-429].  
Epidemiological studies indicate that tobacco smoking exerts anti-estrogenic 
effects that manifest clinically in an early natural menopause, a lowered risk of cancer 
of the endometrium, and an increased risk of some osteoporotic fractures in female 
smokers. Moreover, women who smoke may have a reduced risk of uterine fibroids, 
and endometriosis [430-433].  However, a recent study has indicated that a low dose 
of TSC can exert estrogen-like effects both in vitro and in vivo [434]. TSC has been 
demonstrated to bind and transcriptionally activate ER [435]. Cadmium, a toxic heavy 
metal that occurs in nature and in high levels in cigarette smoke, has been shown to 
increase the steady state levels of ER regulated genes such as pS2 and cathepsin D in 
human breast cancer cells [436]. These findings indicate an estrogenic effect of TSC. 
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Therefore, the role of tobacco smoke in the endocrine modulation associated with 
breast cancer needs further study.  
SULT1E1 is an enzyme that can decrease the hormonal activity of estrogens by 
facilitating their excretion and blocking their ER-mediated activity [233-235]. Since 
estrogen plays a central role in the development and progression of breast cancer 
according to epidemiologic, clinical, as well as molecular and cell biology studies, 
SULT1E1 is well positioned to be a main estrogen modulator and therefore closely 
associated with breast cancer etiology [437;438]. Our data (see Chapter 3) suggest that 
SULT1E1 expression is suppressed by AhR activation. AhR mediated gene 
transcription has been shown to be activated by TSC, and tobacco smoke contains 
PAHs that are known activators of the AhR [435;439]. These findings suggest that TSC 
may suppress SULT1E1 expression through an AhR-mediated mechanism and thereby 
alter estrogen-dependent breast cancer development. In the current study, we 
investigated the effects of TSC treatment on CYP1A1, a well-characterized AhR target 
gene [439], and SULT1E1 expression in the “normal” nontumorigenic human breast 
epithelial cell line MCF10A.   
 
Materials and Methods 
 
Materials.  TSC was prepared by Dr. Deepak Bhalla (College of Pharmacy and Health 
Sciences, Wayne State University). The rest of the materials are as described in 
Chapter 2.  
Cell culture.  As described in Chapter 2. 
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Fig. 4.1 Time-dependent effects of tobacco smoke condensate (TSC) 
treatment on CYP1A1 (A) and SULT1E1 (B) mRNA expression in MCF10A 
cells. Pre-confluent cultures of MCF10A cells were treated for 24, 48, or 72 hr 
with 0, 10 or 50 µg/ml TSC, and CYP1A1 (A) and SULT1E1 (B) mRNA levels 
were measured using TaqMan Gene Expression Assays. CYP1A1 and SULT1E1 
mRNA levels are expressed relative to 24-hr vehicle treated controls, and all 
values represent the mean ± SD of technical replicates of the same sample. 
Gene expression analysis.  As described in Chapter 2 
Transient transfection analysis.  As described in Chapter 2. 
Statistical analysis.  As described in Chapter 2. 
                                        
Results 
 
CYP1A1 has been shown to participate in metabolic activation of PAHs, a typical 
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Fig. 4.2 Effect of AhR antagonist treatment on TSC-mediated 
regulation of CYP1A1 (A) and SULT1E1 (B). MCF10A cells 
were treated for 24 hr with 0.1% DMSO; 2, 10 or 50 μg/ml TSC; or 
30 nM TCDD, alone or in the presence of 1 µM of the AhR 
antagonist 3‟-methoxy-4‟-nitroflavone (MNF). After treatment, the 
cells were harvested for measurement of CYP1A1 (A) and 
SULT1E1 (B) mRNA levels using TaqMan Gene Expression 
Assays. The mRNA contents were expressed relative to the levels 
measured in untreated MCF10A cells and all values represent the 
mean ± SD of technical replicates of the same sample.  
 
class of carcinogenic compounds present in tobacco smoke [404;413;435;440]. 
CYP1A1 expression is inducible by both PAHs and TSC through activation of the AhR  
[435;439]. 
Therefore, 
CYP1A1 
expression was 
used as an 
indicator for 
AhR functional 
activity in the 
present study. 
Treatment of 
MCF10A 
cultures with 10 
or 50 μg/ml TSC 
for 24 hr 
increased 
CYP1A1 mRNA content >50-fold, and this increase persisted for 72h (Fig. 4.1A). When 
the same samples were used to examine SULT1E1 mRNA content it was found that 
TSC treatment attenuated the expression of SULT1E1 in a concentration-dependent 
manner at all time points tested (Fig. 4.1B). Treatment with 10 μg/ml TSC resulted in 
50%, 67% and 70% decreases in SULT1E1 mRNA expression after treatment for 24 hr, 
48 hr, and 72 hr, respectively (Fig. 4.1B), while 50 μg/ml TSC treatment decreased 
85 
 
 
 
NT DMSO 0.1 0.5 1 5 10 30
0
20
40
60
TSC
A A
A
B
B,C
C C
D
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
 A
c
ti
v
it
y
 
Fig. 4.3 Effect of TSC treatment on expression of an AhR-
responsive reporter. MCF10A cells were transiently transfected 
with pGudLuc reporter containing a 484-bp fragment from the 
upstream region of the CYP1A1 gene that includes four dioxin 
responsive element (DRE) [9]. Twenty-four hours post 
transfection, cells were treated with nothing (NT), 0.1% DMSO, or 
0.1–30 μg/ml TSC for 24 h and harvested for measurement of 
luciferase activities. Each bar represents the mean ± S.D. of 
normalized (firefly/Renilla) luciferase measurements (3 wells per 
treatment group). Groups that do not share a capital letter are 
significantly different from each other (p ≤ 0.05). 
  
 
SULT1E1 expression by 75%, 94% and 85%, respectively, at those three treatment 
times (Fig. 4.1B).  
To evaluate whether AhR activation is the mechanistic reason for TSC-mediated 
SULT1E1 suppression, the effects of TCDD, a potent AhR agonist, and MNF, an AhR 
antagonist with little or no agonist activity [441], on CYP1A1 and SULT1E1 mRNA 
levels were tested in MCF10A cells. We first verified that treatment of MCF10A cells 
with the 
prototypical 
AHR agonist, 
TCDD, resulted 
in an ~100-fold 
up-regulation of 
CYP1A1 
(Fig. 4.2A), 
while treatment 
with the AhR 
antagonist, MNF 
(1µM), 
decreased the 
CYP1A1 mRNA level by about 99% relative to vehicle (DMSO) control (Fig. 4.2A). As 
expected, TCDD treatment suppressed SULT1E1 expression by 57% and MNF 
exposure induced a ~5-fold up-regulation of SULT1E1 expression (Fig. 4.2B).   
Treatment with 2, 10 and 50 μg/ml TSC resulted in an induction of CYP1A1 mRNA 
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Fig. 4.4 Effect of MNF treatment on the TSC concentration-
response curves for CYP1A1 induction and SULT1E1 
suppression. MCF10A cells were treated for 24 h with 0.03–
10 μg/ml TSC in the absence or presence of 1 or 3 µM MNF. After 
treatment, the cells were harvested for measurement of CYP1A1 
and SULT1E1 mRNA levels using TaqMan Gene Expression 
Assays. The mRNA contents were expressed relative to the levels 
measured in untreated MCF10A cells and all values represent the 
mean ± SD of technical replicates of the pooled sample of 3 wells 
per treatment group. The fitted sigmoid curve for the data is 
shown, together with the calculated EC50 or IC50 value and 95% 
confidence interval (95% CI).   
  
 
levels of 35-, 169-, and 74-fold, respectively (Fig. 4.2A). By comparison, TSC treatment 
decreased SULT1E1 expression by at least 44% at all of the concentrations that were 
examined (Fig. 4.2B). Co-treatment with MNF abolished TCDD-mediated CYP1A1 
induction and SULT1E1 suppression, but only attenuated ~30% of the 50 µg/ml TSC-
mediated CYP1A1 inductions and had no effect on the suppression of SULT1E1 by 
TSC (Fig. 4.2).  
To confirm the ability of TSC to activate the AhR in MCF10A cells, cells were 
transfected with 
a luciferase 
receptor plasmid 
containing four 
dioxin-response 
elements (i.e., 
AhR binding 
sites), and 
luciferase 
activity was 
measured after 
treatment with 
0.1-30 µg/ml 
TSC for 24h. TSC concentrations of 0.5, 1, 5, 10, 30 µg/ml significantly enhanced 
luciferase reporter expression by 3.3-, 4-, 5-, 4.9-, and 6.6-fold, respectively (Fig. 4.3), 
indicating the activation of AhR. Effects of MNF treatments on the TSC concentration-
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response curves for CYP1A1 induction and SULT1E1 suppression are shown in Fig. 
4.4 MNF treatment inhibited TSC-mediated CYP1A1 induction and SULT1E1 
suppression and shifted the TSC concentration-responsive curves rightwards (Fig. 4.4), 
suggesting a role for the AhR in TSC-mediated CYP1A1 and SULT1E1 regulation.  
 
Discussion 
 
It is well known that the etiology of human breast cancer is affected by complex 
inherited and environmental factors [442;443]. To date, genetic studies have identified 
and confirmed germ-line mutations in high-penetrance genes, such as BRCA1, BRCA2, 
PTEN, and TP53; moderate-penetrance genes, such as ATM, BRIP1, CHEK2, and 
PALB2; and around 20 common low-penetrance variants in 19 genes or loci that 
contribute to a woman's risk of breast cancer [444]. The development of microarray 
approaches enabled genome-wide analysis of breast cancer and identified numerous 
genetic and epigenetic alterations involving a small number of altered signaling 
pathways (PI3K, NK-κB, FGF, etc.) [445]. In addition to these genetic and well accepted 
hormone-related risk factors discussed in the previous chapters, a large number of 
environmental chemicals are suspected of playing a role in breast cancer [26;446;447]. 
For example, traffic emission, the major source of air pollution in urban areas, has been 
associated with increased breast cancer risk among women living close to industrial 
sites and heavy traffic in Long Island, New York [448]. Traffic emissions contain many 
potential carcinogens, such as PAHs, which are also major compounds found in 
tobacco smoke [449]. 
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Tobacco smoke has been associated with increased risk of breast cancer [450]. 
Various factors such as duration and intensity of smoking [451] and tobacco smoking 
during first pregnancy [452] were found to influence the smoking induced risk of breast 
cancer. Moreover, a direct relationship was observed between tobacco smoking and 
metastasis in breast cancer [453]. However, the results of epidemiological studies to 
date have not provided conclusive information about the association between tobacco 
smoking and breast cancer, with some epidemiology studies reporting a positive 
association [300;451;452;454-456] and some reporting a negative association 
[457;458]. The inconsistencies among studies are likely due to the fact that the quantity 
and duration of smoking, age at initiation of smoking, exposure to second hand smoke, 
hormonal profile and gene polymorphisms of the study population are all extremely 
difficult to assess accurately. Investigation of the interaction between tobacco smoke 
and genes that are involved in bioactivation or detoxification processes, in endocrine 
modulation, in DNA repair, and in cell cycle and apoptosis control will provide more 
information about the role of environmental exposure to tobacco smoke in breast 
carcinogenesis. TSC was used as a model to study the effect of tobacco smoke 
exposure. Calculations by Holden et al. [459] suggest that the concentration of 
condensate in the epithelial lining fluid would be 0.01-1% when one cigarette was 
smoked.  
AhR signaling is known to activate both phase I enzymes (most notably 
CYP1A1) and phase II enzymes (mainly glutathione S-transferase Ya) in response to 
tobacco smoke, which will either bioactivate procarcinogens in tobacco smoke or 
sequester and detoxify reactive electrophiles [460-463]. It is therefore plausible that 
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AhR-mediated processes have a measurable and biologically significant effect on the 
carcinogenicity of tobacco smoke. BP, an important component of tobacco smoke, 
induced tumors in wild-type mice, but not in AhR null animals [464]. The results of 
Chapter 3 indicated that the expression of SULT1E1 was subjected to AhR regulation. 
To investigate the inhibitory effect of TSC on SULT1E1 expression, we utilized a 
chemical agonist (TCDD) and antagonist (MNF) to alter AhR signaling in MCF10A cells. 
We found that TSC treatment increased the expression of CYP1A1, a well-
characterized AhR target gene, but suppressed the expression of SULT1E1. Moreover, 
the potency by which TSC suppressed SULT1E1 suppression was greater than the 
potency of CYP1A1 induction. We then confirmed that TSC treatment caused AhR 
activation, as indicated by significant concentration-dependent activation of a transiently 
transfected AhR-responsive reporter plasmid. Co-treatment with the AhR antagonist 
MNF inhibited TSC-mediated CYP1A1 induction, as indicated by MNF-dependent 
rightward shifts of the TSC concentration-response curve. Treatment with MNF alone 
increased SULT1E1 expression and caused rightward shifts of the TSC concentration-
curves, suggesting a role for the AhR in TSC-mediated SULT1E1 suppression. Further 
studies are needed to determine whether tobacco smoke exposure causes SULT1E1 
suppression in the breast in vivo, and whether such an effect plays significant role in 
the development of breast cancer.     
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CHAPTER 5 
 
Knockdown of estrogen-inactivating enzyme SULT1E1 by RNAi accelerates 
tumorigenesis in vivo 
 
INTRODUCTION 
 
Breast cancer is the leading type of cancer and the second most common cause 
of cancer death in American women [1]. Breast cancer incidence rates have decreased 
about 2 percent per year since the early 2000s, possibly due to the use of screening 
mammography and discontinuation of postmenopausal hormone replacement therapy 
(HRT) [465-470]. The latter change probably had a greater effect in that women who 
took HRT to relieve menopausal symptoms had an increased risk of developing breast 
cancer and there was a rapid decline in breast cancer incidence after discontinuation of 
HRT [465-467]. These findings indicate that exogenous estrogen exposure influences 
the development of breast cancer. Moreover, increased cumulative endogenous 
exposure to estrogen resulting from early onset of menarche, later onset of 
menopause, nulliparity, and late age of first pregnancy has also been associated with 
increased breast cancer risk according to the results of clinical and epidemiologic 
studies [22-26]. In addition to the above mentioned evidence linking breast cancer 
incidence to estrogen exposure, clinical and laboratory studies have shown that 
estrogen can directly stimulate the proliferation of human breast cancer cells in vitro 
and drive the growth of breast tumors in vivo [29;30;471-474]. This involvement of 
91 
 
 
 
estrogen in the development and progression of breast cancer provides the conceptual 
basis for the potential use of estrogen modulators as treatments for breast cancer 
[475;476].   
Extensive biotransformation of endogenous and exogenous estrogens to 
estrogen conjugates, especially to abundant circulating estrogen sulfates by SULTs, 
has long been recognized as a major determinant of estrogen levels in humans 
[178;232]. It has been demonstrated that normal human breast epithelial cells possess 
endogenous SULT1E1 activity at physiologically significant levels [341;477]. In contrast, 
many breast cancer cell lines appear to have lost the expression of SULT1E1 and 
therefore lack the high affinity estrogen sulfonation pathway [249;250]. Moreover, 
SULT1E1 has been shown to regulate the in situ bioavailability of estrogen in human 
breast, especially in postmenopausal women [79]. In another study in which specimens 
of human breast carcinoma
 
tissues were used to examine the expression of SULT1E1, 
it was found that SULT1E1 mRNA was expressed in both carcinoma and
 
intratumoral 
stromal cells [97]. It was also demonstrated that SULT1E1 immunoreactivity was 
inversely correlated with tumor
 
size or lymph node status [97]. Moreover, SULT1E1 
immunoreactivity was significantly
 
associated with a decreased risk of recurrence or 
improved prognosis [97]. These studies indicate that SULT1E1 regulates the availability 
of the estrogen in the breast and consequently affects cell growth. We propose that 
SULT1E1 silencing might be a critical event in the transition of normal breast epithelial 
cells to cancer cells by facilitating a breast microenvironment that favors increased 
estrogenic stimulation. 
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The MCF10A-derived lineage of human breast epithelial cell lines is a good 
model to study the molecular events that occur during breast cancer neoplastic 
progression. These MCF10 cell lines were all derived from a common genetic 
background and the model includes the full spectrum of neoplastic progression and 
incorporates aspects of both indolent preneoplastic diseases to aggressively neoplastic 
breast epithelial cell growth. In the current research, we use the premalignant 
MCF10AT1 cell line, which expresses SULT1E1 at a relatively high level (Chapter 2) 
[250], as a model to determine the impact of SULT1E1 silencing on xenograft 
progression. Understanding the function of SULT1E1, the major estrogen-inactivating 
enzyme, will provide new information on in situ estrogen metabolism during human 
breast cancer development. The results of this research will have implications for breast 
cancer prevention and treatment. 
 
Methods and Materials 
 
Materials. Cell culture medium, L-glutamine, horse serum, penicillin-streptomycin 
solution, sodium pyruvate, Lipofectamine 2000, Superscript II, recombinant human 
SULT1E1, and anti-SULT1E1 antibody were purchased from Invitrogen Corporation 
(Carlsbad, CA). EGF was purchased from BD Biosciences (San Jose, CA). 
Recombinant human insulin (Novolin R) was purchased from Novo Nordisk 
Pharmaceuticals, Inc. (Princeton, NJ). Doxycycline, E2, ICI 182780, cholera toxin and 
hydrocortisone were purchased from Sigma-Aldrich (St. Louis, MO). The pS2 antibody 
and orseradish peroxidase-conjugated goat anti-rabbit IgG was purchased from Santa 
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Cruz Biotechnology (Santa Cruz, CA). FuGENE 6 Transfection Reagent was purchased 
from Roche Molecular Biochemicals. ECL Plus Western Blotting Detection Reagents 
and Hybond-P membranes were purchased from GE Healthcare (Piscataway, NJ). All 
materials that were used to produce recombinant lentiviruses targeting human 
SULT1E1 gene were purchased from Addgene (Cambridge, MA), unless otherwise 
stated. Other materials were obtained from the sources indicated below. 
Cell culture. The MCF10AT1 cell line was obtained from the Cell Resources Facility of 
the Barbara Ann Karmanos Cancer Institute, Wayne State University and cultured in 
medium as described in Chapter 2. The human HUVEC cell line was obtained from 
ATCC (Manassas, VA) and maintained in F-12K medium supplemented with 0.1 mg/ml 
heparin, 0.05 mg/ml endothelial cell growth supplement (ECGS) and 10% fetal bovine 
serum at 37 °C with 5% CO2.  
Transient transfection analysis. The p2ERE-luc reporter was constructed by ligating 
a double-stranded oligonucleotide containing two vitellogenin EREs upstream of a 
minimal herpes simplex virus thymidine kinase promoter, which had been preligated 
into pGL3-Basic (Promega Corporation, Madison, WI). The sequences of the 
oligonucleotides are: 5′-CGCGTGTCCAAAGTCAGGTCACAGTGACCTGATTCAGGTC 
ACAGTGACCTGATCAAAGTTA-3′ and 5′-GATCTAACTTTGATCAGGTCACTGTGACC 
TGAATCAGGTCACTGTGACCTGACTTTGGACA-3′.  
MCF10AT1 cells (200,000) were seeded into 24-well plates and cultured in 0.5 
ml phenol red-free DMEM/F12 Nutrient Mixture (1:1) supplemented with 10 μg/ml 
insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone, 10% 
charcoal-stripped fetal bovine serum. The following day, Opti-MEM containing a 
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premixed complex of 4 μl of Lipofectamine 2000, 0.8 μg p2ERE-Luc and 1.25 ng pRL-
SV40 (Promega) was added to each well. The following day, cultures (3 wells per group) 
were incubated with phenol red-free DMEM/F12 Medium, supplemented as described 
above, containing 0.1% DMSO, 0.1, 1 or 10 nM E2. After 48 hr, the cells were 
harvested for measurement of firefly and Renilla luciferase activities using the Dual 
Luciferase Reporter Assay System (Promega) and a Dynex model MLX Luminometer. 
Heterotypic culture of MCF10AT1 and HUVEC cells. Heterotypic three dimensional 
cultures were prepared based on the methods previously reported by Dr. Malathy P. V. 
Shekhar [478]. In brief, 55,000 parental MCF10AT1 cells or MCF10AT1 cells that were 
engineered for conditional knockdown of SULT1E1 expression were mixed with an 
equal number of HUVEC cells and seeded as a single-cell suspension into 96-well 
plates with a solidified layer of phenol red-free Matrigel (100 µl/well) (Collaborative 
Biomedical Products, Bedford, MA). MCF10AT1 cells and HUVEC cells were pre-
labeled with fluorescent cationic membrane tracers, DiI and DiO (Molecular Probes, Inc., 
Eugene, Oregon), respectively, prior to coculturing. For E2 or ICI treatment, 24 hr post 
plating, the co-culture system was treated with E2 or ICI alone or in combination in 
charcoal stripped medium supplemented with EGF and basic fibroblast growth factor 
(bFGF). Cultures were maintained at 37°C for 7 days with daily media changes, and cell 
viability was measured with cellTiTer 96 cell proliferation assays according to the 
manufacturer‟s directions (Promega Corp., Madison, WI). For the trypan blue exclusion 
assay, 100,000 parental MCF10AT1 cells or SULT1E1 knockdown (siSULT1E1) 
MCF10AT1 cells were mixed with an equal number of HUVEC cells and seeded as a 
single-cell suspension into 24-well plates with solidified layer of phenol red-free Matrigel 
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(400 µl/well). After the same E2 or ICI182,780 treatment for 7 days, the medium was 
removed and wells were rinsed with PBS. Matrigel was digested and cells were 
recovered with Cell Recovery Solution (Collaborative Biomedical Products, Bedford, MA) 
according to manufacturer‟s instruction. Cells recovered were then treated with trypsin 
to get single cells. The number of viable cells was determined by trypan blue solution in 
a hemocytometer.   
SULT1E1 conditional knockdown. To prepare a recombinant lentivirus expressing 
shRNA oligonucleotides targeting SULT1E1 in a conditional manner, oligonucleotides 
corresponding to the most effective shRNA that was tested, 
5‟-CGCGTCGCCAGAAATTGACGCCCTTCATCTCGAGATGAAGGGCGACAATTTCTGGCTTTTTTAT-3‟  
and 5‟-CGATAAAAAAGCCAGAAATTGTCGCCCTTCATCTCGAGATGAAGGGCGTCAATTTCTGGC-3‟ 
(Integrated DNA Technologies, INC), were ligated into the MluI and ClaI sites of 
pLVTHM lentiviral plasmid, and then the fragment containing the H1 promoter and the 
shRNA sequence was subcloned into the pLVCT-tTRKRAB Tet-on lentiviral plasmid 
opened with MscI and FspI enzymes. This plasmid was cotransfected into 293T cells 
together with psPAX2 (plasmid expressing lentiviral packaging elements) and psMD2.G 
(plasmid expressing vesicular stomatitis virus envelope protein) using FuGENE 6 
Transfection Reagent. Two days following transfection, medium containing lentivirus 
was collected, filtered and stored at -80 °C. The viral titer was estimated by transducing 
MCF10AT1 cells with several dilutions of virus and visualizing green fluorescence, 
which was also expressed by the lentiviral vector. For infection, MCF10AT1 cells were 
plated
 
into 24-well plates (200,000 cells/well). After 16 hr, medium
 
containing 
recombinant lentivirus was added (the multiplicity of infection=1). Following
 
16h of 
incubation, the cells were washed and subcultured, and doxycycline
 
(Dox, Sigma) was 
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added to half of the infected cells at a final concentration
 
of 50 ng/ml. Five days later, 
the cells were harvested and
 
sorted by fluorescence-activated cell sorting. Then 
individual clones were prepared by limiting dilution and evaluated for doxycline-
inducible SULT1E1 knockdown using a TaqMan Gene Expression Assay and by 
western blot analysis. 
TaqMan Gene Expression assays. As described in Chapter 2. 
Western blot analysis. As described in Chapter 2. 
Mouse xenografts. siSULT1E1 MCF10AT1 cells were grown in T150 flasks and 
harvested at 70-80% confluency. Approximately 3-4 hr before harvesting, culture 
medium was replaced with fresh medium to remove dead and detached cells. Cells 
were then trypsinized and live cells were counted after trypan blue staining using a 
hemocytometer. Approximately 1x10
7
 cells/site in 150–200 μl of Matrigel (Collaborative 
Biomedical Products, Bedford, MA) were inoculated subcutaneously in female nude 
mice aged 55-65 days (NCRNU-M-F, Taconic Farms) at 2 sites/animal using a 21-
gauge syringe. One week after injection, half of the mice were given doxycycline in the 
drinking water (final concentration 2 mg/ml) in water bottles that were wrapped in 
autoclaved alumininum foil. Fresh water containing doxycycline was prepared every 
other day. Twelve weeks after injection, mice were killed and xenograft lesions were 
formalin-fixed and provided to the Microscopy, Imaging & Cytometry Resources (MICR) 
Core Facility (Wayne State University, School of Medicine) for histologic and 
immunohistochemical analysis. These epithelial structures were graded
 
from 0 to 5 
according to the histological classification of
 
Dawson et al. [319]. Xenografts were then 
classified according to the highest grade presented in the lesion. This experiment was 
97 
 
 
 
repeated 3 times and included a total of 14 mice for each group. Experimental protocols 
were approved by the Institutional Animal Care and Use Committee of Wayne State 
University, and guidelines relating to the ethical treatment of animals and relating to 
tissue growth and burden were strictly followed. 
Immunohistochemical staining (IHC). The following procedures were done by the 
MICR Core Facility. Four samples from each treatment group (control and doxycycline-
treated) were used for IHC analysis. Micron sections obtained from formalin-fixed, 
paraffin-embedded tissue blocks were deparaffinized, rehydrated and microwaved on 
high twice for five min in 1 mM sodium citrate buffer, pH 6.0. The sections were then 
washed three times in PBS and blocked with Super Block (Skytek Laboratories, Logan, 
UT) for ten min. Sequential sections were then incubated with the selected primary 
antibodies overnight at 4° C. The sections were then washed three times for 10 min 
each in PBS and linked with the appropriate host secondary antibodies (Vector 
Laboratories, Burlingame, Ca). The secondary antibodies were tagged with avidin-
biotinylated horseradish peroxidase, colorized with 3‟-3‟-diaminobenzidine and 
counterstained with hematoxilin. Visualization and documentation were accomplished 
with an OLYMPUS BX40 microscope supported by a DP72 CCD Camera, and 
CellSens Dimension imaging software (Olympus America Inc., Center Valley, PA). The 
slides were reviewed by Dr. Fred Miller (Professor, Karmanos Cancer Institute, WSU) 
who confirmed the tumor grading. To assess SULT1E1 and pS2 protein levels, 4 
brown-positive and blue-negative IHC stained slides from each group were counted and 
measured using CellSens digital imaging software (Olympus). Three replicates per slide 
were analyzed at 40×magnification. The mean percentage of brown-positive IHC stain 
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Fig. 5.1 E2-mediated activation of an 
estrogen-responsive reporter gene in 
MCF10AT1 cells. MCF10AT1 cells were 
transiently transfected with an estrogen-
responsive luciferase reporter plasmid. After 
transfection, cells were treated with 0.1% 
DMSO, 0.1, 1 or 10 nM E2 for 48 h. After 
treatment, cells were harvested for the 
measurement of luciferase activities. Each bar 
represents the mean ± sd of normalized 
(firefly/Renilla) luciferase measurements 
(3 wells per treatment group) relative to the 
activity measured in DMSO-treated cells. 
Groups that do not share a capital letter are 
significantly different from each other (p<0.05) 
was determined and statistically analyzed using Prism (GraphPad Software, San Diego, 
CA). 
Statistical analysis.  As described in Chapter 2.   
 
Results 
 
It has been reported that SULT1E1 was robustly expressed in the MCF10AT1 
cell line suggesting that estrogen inactivation through sulfonation is intact in MCF10AT1 
cells [250]. The MCF10AT1 cell 
line will therefore provide us with a 
good platform to study the 
biological role of SULT1E1 in 
breast epithelial estrogen 
metabolism. The MCF10A lineage 
is a model for basal breast cancer 
and it has been previously 
reported that MCF10AT1 cells 
express a negligible level of ERα 
when compared to the ERα-
positive MCF7 cell line [250]. 
However, ERα expression levels 
are sufficient in MCF10AT1 cells to 
produce responses to estrogen in 
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vitro and, more importantly, in the MCF10AT1 mice xenograft model [317]. This 
estrogen sensitive nature of MCF10AT1 cells was confirmed using an ER-responsive 
reporter (Fig. 5.1). These findings make MCF10AT1 a good model to study the role of 
SULT1E1 as a mediator of endogenous estrogen responses.  
 
 
 
Fig. 5.2 Growth stimulation effects of estrogen on three-dimensional cultures 
of MCF10AT1 and HUVEC cells. The heterotypic three dimensional cultures were 
treated with vehicle (0.01% DMSO), the indicated concentration of E2, ICI alone, or 
E2 combined with a 100-fold excess of ICI for 7 days. Cell viability was quantitated 
by the trypan blue exclusion assay (A) and cell proliferation was quantitated by MTS 
assay (B) on day 7 of culture. Results are from three independent experiments 
performed in triplicate. Groups that do not share a capital letter are significantly 
different from each other (p<0.05). In panel A, each bar represents the mean cell 
number ± sd. In panel B, data are expressed relative to DMSO-treated cells as 
mean ± sd. 
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Breast epithelial cells cultured in monolayer lack interactions with other cell types 
that are present in whole breast, such as endothelial cells. These intercellular 
interactions will affect the growth as well as drug and hormone sensitivity of breast 
cancer cells [479]. The in vitro three-dimensional culture system reported by Dr. 
Malathy P. V. Shekhar recapitulates in vivo interaction between epithelial and 
endothelial cells [478;480]. Most importantly, this system has been shown to mimic the 
E2-ER induced in vivo effects associated with early angiogenesis and the proliferative 
 
 
Fig. 5.3 SULT1E1 expression in MCF10AT1 cells engineered for conditional 
knockdown of SULT1E1. MCF10AT1 cells engineered for conditional 
knockdown of SULT1E1 were treated for 5 days with 0.1% DMSO or 50 ng/ml 
doxycycline and harvested for measurement of SULT1E1 mRNA (A) and 
immunoreactive protein (B) levels. MCT10AT1 cells engineered to express a 
short-hairpin sequence targeting no known human gene (NT) were used as 
control. A: SULT1E1 mRNA levels were measured in 3 independent experiments 
using a TaqMan Gene Expression Assay. Groups that do not share a capital letter 
are significantly different from each other (p<0.001). B: SULT1E1 immunoreactive 
protein levels were measured by western blot hybridization (experiments were 
repeated at least 3 times). 
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Fig. 5.4 Effects of SULT1E1 knockdown on the estrogen-regulated growth of 
three-dimensional cultures of MCF10AT1 and HUVEC cells. A: MCF10AT1 and 
HUVEC cells were harvested at approximately 70% confluency and SULT1E1 
mRNA levels were measured in 3 independent experiments using a TaqMan Gene 
Expression Assay. Data are expressed as mean ± sd, and ***p<0.001 compared to 
MCF10AT1 cells. B: MCF10AT1 cells engineered for conditional knockdown of 
SULT1E1 were co-cultured with HUVEC cells in three dimensional cultures and 
treated with vehicle (0.01% DMSO), the indicated concentration of E2, ICI alone, or 
E2 combined with a 100-fold excess of ICI for 7 days. Growth was quantitated by the 
MTS assay on day 7 of culture. Data are expressed relative to DMSO-treated cells 
as mean ± sd. Groups that do not share a capital letter are significantly different 
from each other (p<0.05). 
potential of MCF10AT xenografts [478]. Therefore, the estrogen responsiveness of 
MCF10AT1 cells was investigated using both MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carbo xymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and trypan blue exclusion 
assays in heterotypic three-dimensional cultures of MCF10AT1 and HUVEC cells (Fig. 
5.2). Many methods were used to measure cell proliferation. Trypan blue exclusion 
assay is a traditional cell counting method, which is simple and inexpensive. However, 
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Fig. 5.5 IHC staining for SULT1E1 and pS2 in xenograft lesions. MCF10AT1 
cells engineered for conditional knockdown of SULT1E1 were inoculated 
subcutaneously in female nude mice. Half of the mice were given doxycycline in the 
drinking water. Twelve weeks post injection, mice were sacrificed and 4 lesions from 
each group were analyzed by IHC. One representative IHC results from each group 
was shown. Immunostaining for human SULT1E1 (brown staining) was found in 
xenografts from the control group but was dramatically decreased in xenografts 
from the doxycycline-treated group. In contrast, immunostaining for the estrogen-
responsive gene pS2 (brown staining) was higher in xenografts from the 
doxycycline-treated group (40×). 
this method is time consuming and has been reported to be inaccurate [481]. Instead, 
measurement of mitochondrial metabolic rate using MTS to indirectly reflect viable cell 
numbers was well accepted as an alternative method to measure cell proliferation. 
However, metabolic activity may be affected by treatments which can cause significant 
variation in results [482]. Therefore, both of these methods were used to accurately 
assess the effect of SULT1E1 knockdown on cell proliferation. Treatment with 1, 10 
and 100 nM E2 significantly increased cell proliferation in a dose dependent manner by 
at least 3-fold (Fig. 5.2A). These effects were blocked by 100 nM, 1 µM and 10 µM of 
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the antiestrogen ICI, indicating that these growth stimulating effects were E2-specific 
(Fig. 5.2A). The results of the MTS assay were in good agreement with those obtained 
with the trypan blue exclusion assay, except that 1 µM E2 treatment was significantly 
increase cell proliferation. However, E2 treatment did not produce a dose-response, 
which was likely due to the saturation of the MTS assay (Fig. 5.2B).  
To investigate the role of SULT1E1 in estrogen-dependent tumorigenisis, 
MCF10AT1 cells were engineered for knockdown of SULT1E1 expression 
(siSULT1E1). First, transduction-ready lentiviral particles expressing short hairpin RNA 
(shRNA) (MISSION™ TRC-Hs 1.0) were used to knockdown SULT1E1 gene 
expression in MCF10AT1 cells. SULT1E1 lentiviral transduction particles consisted of 
five (A-E) individual constructs targeting different regions of gene sequence. MISSION® 
Non-Target (NT) shRNA was used as a negative control in experiments with the 
MISSION shRNA target set. NT viral vector contained four base pair mismatches within 
the short hairpin sequence to any known human or mouse genes. Real-time RT-PCR 
and western blot data (data not shown) revealed that different constructs had different 
knockdown efficiencies. The most efficient “A” construct knocked down 92% of 
SULT1E1 mRNA expression (data not shown). The other four constructs knocked down 
52-85% of SULT1E1 mRNA expression. Correspondingly, western blot data showed 
that SULT1E1 protein was detected in Non-targeted shRNA transduced cells but not in 
the SULT1E1 shRNA transduced cells (data not shown).   
This MISSIONTM lentiviral system allowed us to identify an shRNA construct for 
efficient SULT1E1 knockdown quickly and easily. In this MISSION™ RNAi system, after 
lentiviral particles transduction, the shRNA sequence is stably integrated into the cell's 
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Fig. 5.6 Quantitative expression of SULT1E1 in xenograft lesions. To assess 
SULT1E1 (A) and pS2 (B) protein levels, immunohistochemically stained slides 
were analyzed for brown-positive and blue-negative content using CellSens digital 
imaging software (Olympus). Data represent the mean percentages of brown-
positive stain. ** p<0.01 ***p<0.001 (n=12). C: Four lesions from each group were 
used to analyze the SULT1E1 mRNA level by TaqMan Gene Expression Assay. 
Data are expressed relative to control group as mean ± sd. ***p<0.001  
 
genome, and the shRNA is constantly expressed in the cell leading to the continuous 
knockdown of SULT1E1 expression. This should elevate the level of biologically active 
estrogens in the cells and increase the expression of estrogen responsive genes. 
However, continuous knockdown of SULT1E1 may produce undesired effects. For 
example, stable expression of SULT1E1 in MCF7 cells extensively inhibited cell growth 
[247]. Therefore, a reversible, drug-regulated lentiviral Tet-on system that permits 
conditional expression of SULT1E1 was employed.  
The shRNA fragment of selected “A” construct was inserted into the lentiviral 
vector of the Tet-on system for drug inducible production of shRNA in stably transduced 
MCF10AT1 cells. In the presence of doxycycline, shRNA targeting SULT1E1 will be 
expressed and SULT1E1 gene will be down-regulated [483]. This controlled shRNA 
expression system facilitates the comparison of the behavior changes of the cells 
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developed from the same cell colony before or after doxycycline treatment. The same 
genetic background of the cells make it possible to focus only on the molecular events 
produced by SULT1E1 knocking down.  
MCF10AT1 cells that were engineered to express a short-hairpin sequence 
targeting no known human gene (NT) were used as a control (Fig. 5.3A). In the 
presence of doxycycline, the short-hairpin sequence targeting SULT1E1 produced 
significant knockdown of SULT1E1 mRNA content (by 53%), which was accompanied 
by a marked decrease in SULT1E1 immunoreactive protein levels (Fig. 5.3). In contrast, 
the NT control displayed neither SULT1E1 mRNA nor protein level changes after 
doxycycline treatment (Fig. 5.3). To characterize the effect of SULT1E1 in vitro, 
siSULT1E1 cells were used to repeat the MTS assay in the heterotypic culture system 
(Fig. 5.4B). In order to rule out the possibility that SULT1E1 expressed by the HUVEC 
cells might have contributed to estrogen metabolism, real-time RT-PCR was used to 
measure SULT1E1 expression in MCF10AT1 and HUVEC cells (Fig. 5.4A). HUVEC 
cells express an extremely low level of SULT1E1 mRNA compared to MCF10AT1 cells 
(Fig.5.4A). SULT1E1 knockdown after doxycycline treatment did not cause a significant 
change in the response to estrogen treatment, although 10 nM E2 treatment 
significantly induced a 3-fold and 3.6-fold increase in cell proliferation in the vehicle 
(DMSO) and doxycycline treated groups, respectively (Fig. 5.4B). These results indicate 
that interaction between epithelial and endothelial cells in three-dimensional culture 
system may not be enough to recapitulate the in vivo effect of SULT1E1 knockdown 
due to the differences present in the microenvironment of solid tumors compared with 
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Fig 5.7 Effects of SULT1E1 knockdown on tumorigenicity. A: Representative 
H&E stain of histological grade 2 structures (arrow) for one lesion from the control 
group (10×). B: representative H&E stain of histological grade 4 structures (arrow) 
for one lesion from doxycycline treated group (10×). Duct distension, rounded 
lumens, and enlarged nuclei characterize the grade 4 structure. C: Summary of the 
histological grades of 25 xenografts from the control group and 24 xenografts from 
the doxycycline-treated group. The accumulative incidence of lesion formation was 
64% and 92%, respectively, for the control and doxycycline treated group. 
 
 
 
cells in culture. Therefore, we analyzed the effects of SULT1E1 silencing on the 
progression of siSULT1E1 MCF10AT1 xenografts.  
To rule out the possibility that lentiviral transfection may cause malignant 
transformation, parental MCF10AT1 cells and 3 siSULT1E1 MCF10AT1 clones were 
inoculated subcutaneously in female nude mice (4 mice/ group). According to 
histological evaluation, one of the clones (S15) developed xenografts containing typical 
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MCF10AT1 epithelial
 
structures and was used in the following experiments (data not 
shown). To determine whether doxycycline treatment was capable of suppressing 
SULT1E1 expression in xenograft lesions, IHC and real-time RT-PCR were performed 
(Fig.5.5, 5.6). In the lesions from control group, SULT1E1 was strongly stained as 
brown, but in lesions from doxycycline treated group, the staining was significantly 
suppressed (Fig. 5.5, Fig. 5.6A), indicating that SULT1E1 expression was knocked 
down after the induction of the short-hairpin RNA by doxycycline treatment. The IHC 
negative controls showed no positive staining in the lesions. The SULT1E1 down 
regulation was confirmed by real-time RT-PCR analysis of four lesions from each group 
(Fig. 5.6C). Functionality of the SULT1E1 knockdown on estrogen level changes was 
evaluated by induction of the estrogen-responsive gene pS2 in xenograft lesions (Fig. 
5.5). There was significantly more positive brown staining of pS2 in the SULT1E1 
knockdown samples than there was in the control group indicating enhanced estrogen 
levels in tissues with SULT1E1 knockdown (Fig. 5.5, Fig. 5.6B).Histological evaluation 
(Fig. 5.7) indicated that MCF10AT1 xenografts contained epithelial
 
structures that 
resemble normal breast ducts
 
and ductal epithelial lesions ranging from mild 
hyperplasia
 
to carcinoma in situ. These epithelial structures were graded
 
from 0 to 5 
according to the histological classification of
 
Dawson et al. [319]. Histologic analysis 
done by Dr. Fred Miller (Professor, Karmanos Cancer Institute, WSU) and MICR Core 
Facility (WSU) indicated that 44% of the lesions from the control group (total of 25 
lesions) lacked evidence of epithelial growth, 12% were classified as grade 1, 28% 
were classified as grade 2, and 16% were classified as grade 3. By comparison,
 
92% of 
the lesions from the doxycycline treated group (total of 24 lesions) proliferated; 12.5% 
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of the lesions were classified as grade 1, 62.5% were classified as grade 2, 8.3% were 
classified as grade 3, and 8.3% were classified as grade 4.  There was a dramatic 
difference in the percentage of lesions in the control group and the doxycycline-treated 
group xenografts containing grade
 
2 structures (28 versus 64%, respectively). 
Moreover, only lesions from the doxycycline-treated group advanced to in situ 
carcinoma (8.3% grade 4).   
 
Discussion 
 
The molecular changes that enable normal breast epithelial cells to transform 
into invasive, metastatic cancer cells are being increasingly understood [284;303], and 
gene expression profiles are being used to discriminate among different subtypes of 
breast cancer. Triple-negative breast cancers (TNBC) (ER-, PR-, and HER2-negative) 
have become a focus of intense research since TNBC patients have a younger age at 
onset, higher tumor grade, larger tumor size, increased propensity to develop 
metastases, and most importantly, they lack the three most significant therapeutic 
markers for clinical management resulting in the worst outcome when compared with 
other cancer subtypes [14-17;484]. The MCF10A lineage of cell lines represent a good 
model to study TNBC because the malignant cancer cell lines of this lineage (e.g., 
MCF10CA1) are triple negative [314;315].  
TNBC cells respond to estrogen both in vitro and in xenografts even though they 
do not express ERs [326-330]. ER-negative breast cancer cell line, MDA-MB-468 and 
MDA-MB-231 subclone 10A, demonstrated significant E2-stimulated growth in mouse 
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xenograft models in two separate studies [485;486]. This E2-induced tumor growth was 
abrogated in ER-αKO mice, indicating that ER-α mediated the effect of estrogen on 
tumor growth [485]. Similarly, although MCF10AT1 cells express extremely low levels of 
ERα compared to MCF-7 cells, MCF10AT1 cells exhibited E2-stimulated growth in vitro 
and, more importantly, in the MCF10AT1 mice xenograft model [317]. These E2 
stimulated effects may be mediated through ERβ or cross-talk between ER signaling 
parthway and other signal transduction routes. In the present study, E2 treatments 
significantly increased pre-neoplastic MCF10AT1 proliferation in three-dimensional 
cultures (Fig. 5.2). After E2 exposure, the luciferase activity of p2ERE-Luc reporter was 
significantly enhanced, indicating that ER plays an important role in MCF10AT1 
estrogen responsiveness (Fig. 5.1). 
Moreover, there are also clinical indications that ERα-negative tumors are 
influenced by hormonal factors. For instance, OVX has been shown to reduce long-
term recurrence risk and mortality of both ER-positive and ER-negative pre-menopausal 
women [487]. Similarly, a large clinical study done on women carrying BRCA1 or 
BRCA2 mutations demonstrated that OVX significantly reduced cancer incidence in this 
high-risk population (relative risk: 80% versus 19%) [488]. Because the majority of 
breast tumors that develop in women carrying BRCA1 mutations are ERα-negative 
[489;490], this finding indicates that estrogen can affect the pathogenesis of ERα-
negative breast cancers. Therefore, the level of SULT1E1 within breast tissues may 
play a critical role in the maintenance of estrogen balance and protection of breast 
tissues from the adverse effects of estrogen.  
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SULT1E1 expression has been associated with a decreased risk of recurrence  
as well as improved prognosis of breast cancer and its immunoreactivity was inversely 
correlated with tumor
 
size or lymph node status [97]. The genetic polymorphisms of 
SULT1E1 have also been correlated with increased breast cancer risk and a disease 
free survival [97;491]. Moreover, it has been demonstrated SULT1E1 may also protect 
human breast by catalyzing the sulfonation of carcinogenic estrogen metabolites such 
as catecholestrogens (CEs) and methoxyestrogens (MEs) [492]. Since most breast 
cancer cell lines lose SULT1E1 expression [249;250], SULT1E1 silencing might be a 
critical event in the transition of normal breast epithelial cells to cancer cells by 
facilitating a breast microenvironment that favors increased estrogenic stimulation. 
Knockdown of SULT1E1 did not significantly change estrogen stimulated 
MCF10AT1 cell proliferation in three-dimensional culture in the present study. This may 
be caused by the differences present in the microenvironment of solid tumors in vivo 
compared with cells in culture. It has been demonstrated that specific genes may be 
regulated differently in vivo vs in vitro. For example, only 11% of E2-responsive genes 
identified in E2 treated T47D human breast cancer cells xenografted into in nude mice 
overlapped with those E2-regulated genes found in the identical cells grown in cultures 
[493]. Nude mice are valuable research tools because they do not have rejection 
response. The transplanted human cells can proliferate and thereby permit in vivo study 
of the human cells. Therefore, the effect of SULT1E1 silencing in pre-neoplastic 
MCF10AT1 cells on tumorigenicity was studied in a nude mouse xenograft model.  
SULT1E1 knockdown increased the cumulative incidence of xenograft lesion 
formation (from 64% in the control group to 92% in the doxycycline-treated group), 
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cellularity and histological grade of xenografts in immunodeficient mice. Moreover, the 
expression of the estrogen-responsive gene pS2 was low in the control group, which is 
consistent with the finding that pS2 is only expressed in ER-positive breast cancers 
[494;495], but was significantly enhanced in the SULT1E1 knockdown group. These 
findings indicate that SULT1E1 down-regulation activates the estrogen-responsive gene 
pS2 by increasing bioactive estrogen levels and accelerates estrogen-dependent 
tumorigenicity.  
Most breast cancer patients are postmenopausal women who lack estrogen 
produced in ovary. However, the estrogen concentrations in the breast tissue of 
postmenopausal patients are similar to those of premenopausal women indicating in 
situ estrogen synthesis [496]. OVX mice supplemented with exogenous estrogen 
simulate the in vivo situation in the postmenopausal breast cancer patient. The effect of 
SULT1E1 knockdown on estrogen-dependent tumor growth can be further studied in 
OVX mice treated with or without estrogen. These studies will provide additional 
information about the interplay of SULT1E1 and estrogen during breast carcinogenesis, 
which might have implications for the prevention of TNBC. 
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Estrogen sulfotransferase (SULT1E1) catalyzes the sulfonation of estrogens, 
which limits estrogen mitogenicity. TaqMan Gene Expression assays were used to 
profile the mRNA expression of estrogen receptor (ERα and ERβ) and estrogen 
metabolism enzymes including cytosolic sulfotransferases (SULT1E1, SULT1A1, 
SULT2A1, and SULT2B1), steroid sulfatase (STS), aromatase (CYP19), 17β-
hydroxysteroid dehydrogenases (17βHSD1 and 2), CYP1B1, and COMT in an 
MCF10A-derived lineage cell culture model for basal-like human breast cancer 
progression and in ERα-positive luminal MCF7 breast cancer cells. Low levels of ERα 
and ERβ mRNA were present in MCF10A-derived cell lines. SULT1E1 mRNA was 
more abundant in confluent relative to pre-confluent MCF10A cells, a non-tumorigenic 
proliferative breast disease cell line. SULT1E1 was also expressed in preneoplastic 
MCF10AT1 and MCF10AT1K.cl2 cells, but was markedly repressed in neoplastic 
MCF10A-derived cell lines as well as in MCF7 cells. Steroid-metabolizing enzymes 
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SULT1A1 and SULT2B1 were only expressed in MCF7 cells. STS and COMT were 
widely detected across cell lines. Pro-estrogenic 17βHSD1 mRNA was most abundant 
in neoplastic MCF10CA1a and MCF10DCIS.com cells, while 17βHSD2 mRNA was 
more prominent in parental MCF10A cells. CYP1B1 mRNA was most abundant in 
MCF7 cells. Treatment with the histone deacetylase inhibitor TSA induced SULT1E1 
and CYP19 mRNA but suppressed CYP1B1, STS, COMT, 17βHSD1, and 17βHSD2 
mRNA in MCF10A lineage cell lines. In MCF7 cells, TSA treatment suppressed ERα, 
CYP1B1, STS, COMT, SULT1A1, and SULT2B1 but induced ERβ, CYP19 and 
SULT2A1 mRNA expression. The results indicate that relative to the MCF7 breast 
cancer cell line, key determinants of breast estrogen metabolism are differentially 
regulated in the MCF10A-derived lineage model for breast cancer progression. 
We recently reported that SULT1E1 expression is low in pre-confluent MCF10A 
breast epithelial cells but increases when the cells become confluent. Pulse-chase 
labeling experiments with bromouridine demonstrated that the confluence-mediated 
increase in SULT1E1 expression was due to increased mRNA synthesis. Because AhR 
activation has been shown to suppress SULT1E1 expression and loss of cell-cell 
contact has been shown to activate AhR in other cell types, we tested whether the 
confluency-associated changes in SULT1E1 expression were mediated by the AhR. 
Relative to confluent MCF10A cells, pre-confluent cells had higher levels of CYP1A1 
mRNA and greater activation of an AhR-responsive luciferase reporter, demonstrating 
that AhR was active in the pre-confluent cells. AhR and ARNT mRNA and protein levels 
were also higher in pre-confluent than in confluent cultures. Treatment of pre-confluent 
cells with the AhR antagonist, MNF, or AhR knockdown significantly increased 
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SULT1E1 expression. MCF10A cells stably transfected with a luciferase reporter 
containing ~7 kb of the SULT1E1 5‟-flanking region showed both MNF- and confluence-
inducible luciferase expression. Pre-confluent cells transiently transfected with the 
reporter showed both MNF treatment- and AhR knockdown-mediated luciferase 
induction, but mutation of a computationally predicted dioxin response element (DRE) 
at nt -3476 did not attenuate these effects. These results demonstrate that SULT1E1 
expression in MCF10A cells is transcriptionally regulated by confluency through a 
suppressive action of the AhR, which is not mediated through a DRE at nt -3476. 
Tobacco smoke has been implicated as a risk factor for breast cancer. We evaluated 
the effect of TSC on expression of the estrogen-inactivating enzyme SULT1E1 in the 
MCF10A human breast epithelial cell line. Because TSC contains components that are 
known AhR agonists, effects of TSC treatment were compared to those of TCDD, and 
effects on SULT1E1 expression were compared to those on CYP1A1. Treatment for 
24-72 h with 0.05-10 µg/ml TSC produced concentration-dependent increases in 
CYP1A1 mRNA content, decreases in SULT1E1 mRNA content, and increases in 
expression from a transfected AhR-responsive reporter plasmid. Treatment with 10 
µg/ml TSC and 30 nM TCDD produced comparable increases in CYP1A1 mRNA levels 
(~300-fold) and decreases in SULT1E1 mRNA levels (~90%). Treatment with the AhR 
antagonist 3'-methyl-4'-nitroflavone (MNF, at 1 uM) completely inhibited TCDD-inducible 
CYP1A1 expression and partially reversed TCDD-mediated SULT1E1 suppression. 
MNF also inhibited TSC-mediated CYP1A1 induction and SULT1E1 suppression as 
indicated by rightward shifts of the TSC concentration-response curves. These findings 
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support a role for the AhR in TSC-mediated regulation of CYP1A1 and SULT1E1 
expression in human breast epithelial cells. 
Despite a growing understanding of SULT1E1‟s function in steroid hormone and 
drug metabolism, the role of SULT1E1 in the malignant progression of breast epithelial 
cells is still unknown. In this research, MCF10AT1 cells that have preserved SULT1E1 
expression and E2-ER regulative growth kinetics was used to determine the impact of 
SULT1E1 expression on tumorigenicity. The effect of SULT1E1 silencing in pre-
neoplastic MCF10AT1 cells on tumorigenicity was studied in nude mice xenografts 
model. The in vivo and in vitro SULT1E1 silencing was confirmed by real-time RT-PCR, 
western blot hybridization and immunohistochemistry staining. This SULT1E1 
knockdown increases the cumulative incidence of xenograft lesions formation (from 
64% in the control group to 92% in the doxycycline treated group), cellularity and 
histological grades of xenografts in immunodeficient mice. Moreover, the expression of 
estrogen responsive gene pS2 was low in control group but was significantly increased 
in SULT1E1 knockdown group. These findings indicate that SULT1E1 down regulation 
activate estrogen responsive gene pS2 by increasing bioactive estrogen level.   
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